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Abstract
The ability to establish a durable pool of memory B (BMEM) cells is not only a key feature of adaptive
immunity but also critical for host survival upon secondary infection. Depending on the nature of the
pathogen, preimmune B cells differentiate into various BMEM cells associated with a particular
immunoglobulin isotype. Moreover, cytokines dictate this process via the induction of transcription factors
resulting in a stable lineage. Recently, the transcription factor, T-BET, has been implicated in reinforcing
BMEM cells of the IgG2c isotype. Further, phenotypically similar cells express the integrin, CD11c, and
appear in humoral autoimmunity and aged mice. However, the activation requisites and extrinsic cues driving
T-BET and CD11c expression remain poorly defined. T follicular helper (TFH) cells instruct B cells to adopt
various BMEM cell fates via the production of cytokines—specifically IL-4, IL-21 and IFNγ. Here we reveal a
novel interplay among these cytokines in determining T-BET+ B cell fate. We find that IL-21 or IFNγ directly
promote T-BET+ B cells in the context of TLR engagement. Further, IL-4 antagonizes IL-21-induced T-BET
expression, but augments that of IFNγ. Finally, IL-21, but not IFNγ, promotes CD11c expression. Using well-
defined infections that drive IL-21 and robust IFNγ or IL-4 production, we show that these same cytokine
interactions function in vivo to determine T-BET and CD11c expression. We elaborate a model in which
abundant IFNγ will drive T-BET+ B cells; however, in the absence of IFNγ, IL-21 and IL-4 reciprocally
regulate both T-BET and CD11c. Importantly, CD11c expression is restricted to BMEM cells, which
phenotypically resemble Age-associated B cells (ABCs). In accord with our infection results, we show that T-
BET+CD11c+ ABCs are likely a pool BMEM cells. Consistent with this idea, ABCs are somatically mutated,
class- switched, and require the ability to present antigen and receive costimulation to form. These findings
suggest that T-BET+ B cells seen in health and autoimmunity share the common initiating features of TLR
driven activation within this circumscribed cytokine milieu.
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ABSTRACT 
INTERPLAY OF IL-4, IL-21, AND IFNγ ON MEMORY B CELL FATE 
DECISIONS 
MARTIN SOUREN NARADIKIAN 
MICHAEL PAUL CANCRO 
The ability to establish a durable pool of memory B (BMEM) cells is not only 
a key feature of adaptive immunity but also critical for host survival upon 
secondary infection.  Depending on the nature of the pathogen, preimmune B 
cells differentiate into various BMEM cells associated with a particular 
immunoglobulin isotype.  Moreover, cytokines dictate this process via the 
induction of transcription factors resulting in a stable lineage.  Recently, the 
transcription factor, T-BET, has been implicated in reinforcing BMEM cells of the 
IgG2c isotype.  Further, phenotypically similar cells express the integrin, CD11c, 
and appear in humoral autoimmunity and aged mice.  However, the activation 
requisites and extrinsic cues driving T-BET and CD11c expression remain poorly 
defined.  T follicular helper (TFH) cells instruct B cells to adopt various BMEM cell 
fates via the production of cytokines—specifically IL-4, IL-21 and IFNγ.  Here we 
reveal a novel interplay among these cytokines in determining T-BET+ B cell fate.  
We find that IL-21 or IFNγ directly promote T-BET+ B cells in the context of TLR 
engagement.  Further, IL-4 antagonizes IL-21-induced T-BET expression, but 
augments that of IFNγ.  Finally, IL-21, but not IFNγ, promotes CD11c expression.  
Using well-defined infections that drive IL-21 and robust IFNγ or IL-4 production, 
we show that these same cytokine interactions function in vivo to determine T-
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BET and CD11c expression. We elaborate a model in which abundant IFNγ will 
drive T-BET+ B cells; however, in the absence of IFNγ, IL-21 and IL-4 reciprocally 
regulate both T-BET and CD11c.  Importantly, CD11c expression is restricted to 
BMEM cells, which phenotypically resemble Age-associated B cells (ABCs).  In 
accord with our infection results, we show that TBET+CD11c+ ABCs are likely a 
pool BMEM cells.  Consistent with this idea, ABCs are somatically mutated, class-
switched, and require the ability to present antigen and receive costimulation to 
form. These findings suggest that TBET+ B cells seen in health and autoimmunity 
share the common initiating features of TLR driven activation within this 
circumscribed cytokine milieu. 
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1. OVERVIEW OF HUMORAL IMMUNITY 
1.1 The innate and adaptive immune response 
Protective immunity relies on establishing appropriate immune effector 
functions during primary responses, then sustaining these qualities in effector 
and memory cell pools. While appropriate effector functions promote lifelong 
immunity, aberrant effector choices can yield failed pathogen clearance, chronic 
inflammation, or autoimmunity.  Current ideas suggest that cooperation between 
the innate and adaptive immune systems rids the vertebrate host of pathogens 
while maintaining tolerance to self.  Indeed, cells in these two branches establish 
a complex network of activating and regulatory interactions that includes both 
cell-to-cell contacts and extracellular signals.  Myeloid cells including DCs, 
eosinophils, basophils, neutrophils, MΦs, mast cells, comprise the innate system 
and are considered the rapid, first line of defense against tissue-invading 
pathogens.  Further, myeloid cells express germline-encoded PRRs imparting 
recognition of and specificity for evolutionarily conserved PAMPs (1).  
Importantly, although PAMPs are typically associated with microbes, mammalian 
cellular products can also trigger PRRs.  Regardless of the source of PAMPs, 
engagement with PRRs communicates activation signals.  Once initiated, these 
responses foster differentiative programs that direct particular effector choices for 
the subsequent activation and regulation of the adaptive immune response (2, 3). 
In contrast to innate lineages, two lymphoid lineages, T and B cells, are 
the primary mediators of adaptive immune responses.  Each builds a unique 
antigen receptor (TCRs and BCRs, respectively) via a process of gene 
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rearrangement.  In accord with the clonal selection paradigm (4), these 
somatically generated receptors are clonally distributed among lymphocytes such 
that each T and B cell expresses only one antigen receptor specificity.  
Moreover, receptor engagement beyond a requisite threshold affords specificity 
and triggers robust intracellular signaling cascades.  Once activated, 
lymphocytes possess the unique capacity to generate long-term memory cells of 
related pathogen-reactive clones, which often impart protection against 
secondary infection.  Importantly, lymphocytes accomplish their effector functions 
while also maintaining tolerance to the host.  Thus, the tenets of the adaptive 
immune system–specificity, inducibility, memory, and tolerance—are key aspects 
of cell-mediated and humoral immunity as established by T and B cells, 
respectively. 
In order to orchestrate cell-mediated immunity, T cells recognize antigenic 
peptides presented on MHC molecules via the TCR.  The coreceptors, CD4 and 
CD8, define two functionally distinct subsets of T cells that engage antigen in the 
context of MHCII and MHCI molecules, respectively.  CD8 T cells, or CTL, are 
responsible for lysing cells that present non-self peptides in the context of MHCI 
on their surface.  Further, nearly every nucleated cell expresses MHCI 
molecules, which are loaded with peptide via the cytosolic pathway, thus allowing 
for broad surveillance of intracellular protein synthesis.  Conversely, CD4 T cells, 
or helper T cells, generally orchestrate immune responses by recognizing non-
self peptides in the context of MHCII on the surface of APCs such as DCs, B 
cells, or MΦs.  Importantly, CD4 T cells monitor extracellular proteins since 
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MHCII expression is restricted to phagocytic cell types and peptide loading 
occurs via the endocytic pathway.  Furthermore, helper T cells have the capacity 
to differentiate into several effector subsets: TH1, TH2, TH17, TFH, or Treg (5-8).  
The cues guiding these cell fate decisions likely involve the nature of the 
pathogen, the PAMPs it carries, and how innate and adaptive cells integrate PRR 
signals.  Further, master transcriptional regulators that reinforce particular fates 
frequently characterize these effector differentiation patterns.  Thus, preimmune 
CD4 T helper cells adopt alternative effector fates based on TCR signal strength, 
costimulatory cues, and cytokine milieu (9-12). 
Analogously, B cells can adopt a variety of distinct effector fates that are 
similarly guided by BCR signal strength coupled with additional cues that foster 
key transcriptional programs to establish humoral immunity.  Importantly, B cells 
also express certain PRRs and respond to PAMPs.  Coupled with the BCR, 
integration of these signals ultimately drives antibody production, antigen 
presentation and costimulatory interactions with CD4 T cells, and cytokine 
secretion.  Principally among these functions, the Ig produced consists of 
identical sets of heavy and light chains joined together by disulfide bonds.  Both 
chains combine to form the antigen binding or CDR, whereas only the heavy 
chain forms the Fc region which imparts antibody effector functions.  Five main 
heavy chain isotypes, µ, δ, γ, ε, and α, combine with either a λ or κ light chain to 
make an IgM, IgD, IgG, IgE, or IgA respectively.  Moreover, the IgG isotypes can 
be subdivided into IgG1, IgG2a/c (IgG2a for BALB/c and IgG2c for C57BL/6, (13)), 
IgG2b, or IgG3.  Similar to cell fate decisions in T helper cells, B cells adopt an 
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isotype based on the prevailing cytokine meilieu and subsequently induced 
master transcriptional regulator.  The nature, levels, and persistence of Ig heavy 
chain isotypes that are provoked have profound implications for response quality.  
Indeed, nearly all heavy chain isotypes link adaptive humoral responses with a 
circumscribed group of innate inflammatory cells and systems important for 
pathogen clearance, such as complement fixation, opsonization, degranulation, 
and ADCC.  These effector processes rely on isotype-specific Fc receptors that 
are differentially distributed among innate, myeloid, and other cell types.  Since 
FcR can be either activating or inhibitory, Ig isotype engagement can either 
enhance or limit the activation and behavior of these cells (14).  While marshaling 
these FcR effector systems is critical to effective humoral immunity, the same 
effector mechanisms mediate autoimmune and chronic inflammatory pathologies.  
Thus, the importance of these Ig:FcR interactions are apparent, yet to generate a 
protective antibody of the proper effector isotype requires strict regulation of B 
cell development, homeostasis, and activation. 
1.2 B lymphocyte commitment, development, and homeostasis 
 B cells can be separated into two lineages: B-1 and B-2.  Debate remains 
as to whether B-1 and B-2 cells derive from a common progenitor and diverge 
based on antigen-driven selection, or instead reflect the products of distinct, 
lineage-restricted progenitors (15-17).  Regardless of their exact origins, each 
lineage plays distinct yet overlapping roles in humoral immunity, reflecting 
differences in their generation, antigen receptor diversity, and anatomic niche.  
Murine B-1 cells are derived primarily from the fetal liver, and are sustained 
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largely by self-renewal in the periphery (15, 16, 18, 19).  In contrast, continuous 
B-2 cell production yields a much larger steady-state pool throughout life (20).  B-
2 cell subsets are defined by surface marker criteria that are correlated with 
developmental stage, activation status, recirculation properties, and anatomic 
locale.  Table 1 summarizes these criteria, features, and transcriptional 
regulators for developing and preimmune B cell subsets.  In healthy adults, B 
cells are generated continuously from hematopoietic stem cells in the bone 
marrow (BM), where Ig heavy and light chain gene rearrangements are 
completed during the pro- and pre-B cell stages respectively (21) (reviewed in 
(22, 23)).  Commitment to the B lineage involves both the acquisition of a B cell 
transcriptional program and the suppression of programs leading to other 
hematopoietic fates (24).  Accordingly, adoption of B lineage fate involves the 
expression of PAX5 (25-27), EBF1 (28-31), and E2A proteins (32, 33), which 
establish a transcriptional circuit that not only induces and reinforces B lineage 
genes, but also represses transcription factors driving alternate lineages (34).  
Upon acquisition of surface IgM, developing B cells enter the IMM subset.  These 
cells migrate to the periphery via the blood and pass through the TR 
developmental stages before entering the comparatively long-lived mature FO or 
MZ B cell pools (35-40).  The cues required to adopt the MZ instead of FO B cell 
fate include tonic BCR signal strength and transcriptional programs driven by 
Notch2 (41) interactions with Delta-Like-1 (42, 43) reviewed in (44). 
 Stringent selection based on BCR specificity occurs during both the IMM 
and TR stages: only 10% of IMM cells produced survive to exit the marrow, and 
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Table I:  Features of developing and preimmune B cell subsets 
 
 
  
Locale B cell subset Surface phenotype 
Transcription 
Factors 
BLyS 
receptors 
Survival 
cytokine 
BM 
 pro-B 
CD19+, CD43+, CD93+, 
IgM-, IgD- 
 
PAX5 
none IL7 
 pre-B 
CD19+, CD43-, CD93+,  
IgM-, IgD- 
 
PAX5 
none ? 
 IMM 
CD19+, CD93+, IgMhi, 
IgDlo/- 
 
PAX5 
BR3/TACI ? 
Spleen/ 
Blood  TR 
CD19+, CD93+, CD43-, 
IgMhi, IgDlo/-, CD21-, 
CD23- 
PAX5 
TACI/BR3 BLyS 
Blood, 
lymph, 
spleen 
 FO 
CD19+, CD93-, CD43-, 
IgMlo, IgDhi, CD21lo, 
CD23+ 
PAX5 
TACI/BR3 BLyS 
MZ 
CD19+, CD93-, CD43-, 
IgMhi, IgDlo, CD21+, 
CD23lo 
Notch targets 
TACI/BR3 BLyS 
Lymph 
nodes, 
Spleen 
GC 
(DZ) 
CD19+, IgM-, IgD-, 
PNA+, CD95+, 
CXCR4+, CD83- 
BCL6 
BR3 BLyS 
GC 
(LZ) 
CD19+, IgM-, IgD-, 
CD23+, PNA+, CD95+, 
CXCR4-, CD83+ 
BCL6 
BR3 BLyS 
 
Spleen 
Blood, 
BM 
SLPC 
CD19+, B220+, IgM+/-, 
IgD-, CD138hi 
 
BLIMP1 
TACI/ 
BCMA 
APRIL? 
BLyS? 
IL6 
 LLPC 
CD19-, B220-, IgM-, 
IgD-, CD138hi 
BLIMP1 
BCMA APRIL? 
 
Sw 
Bmem 
CD19+, IgM-, IgD-, 
CD38+, PDL2+/-, 
CD73+/-, CD80+/- 
? 
BR3 ? 
 
IgM 
Bmem 
CD19+, IgM+, IgD-, 
CD38+, PDL2+/-, 
CD73+/-, CD80+/- 
? 
BR3 ? 
Spleen. 
Blood, 
BM, 
Tissue 
ABC 
 
CD19+, CD93-, CD43-, 
IgM+/-, IgD+/-, CD21-, 
CD23-, CD11c+/- 
 
 
T-BET BR3/TACI ? 
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only 30% of the TR cells thus generated survive to join the FO or MZ pools (36).  
These profound cell losses reflect both negative and positive selection based on 
BCR signal strength (45-51), presumably reducing the frequency of polyreactive 
and self-reactive specificities (46, 48, 52), as well as selecting for cells with 
optimal sub-threshold signal strength (47, 51, 53, 54). Indeed, multiple studies 
now indicate that the representation of frankly autoreactive B cell specificities in 
each pool decreases at each successive differentiation stage (55, 56).  Thus, 
among peripheral B cells, the TR pool is a rich source of autoreactive BCR 
specificities compared to most other B cell subsets (57). 
 The steady-state sizes of preimmune FO and MZ B cell pools are 
controlled by the TNF family member, B cell activating factor (BAFF) (58, 59) 
(reviewed in (60)). This cytokine sustains FO and MZ B cell survival by signals 
delivered through BAFF receptor (BAFFR) (61-65). All TR, FO, MZ B cells 
express BAFFR (66, 67) and compete continuously for BAFF to survive, such 
that available systemic BAFF determines their lifespan and thus overall FO and 
MZ pool sizes ((62, 63), reviewed in (68)).  Because the steady-state size of pre-
immune B cell pools is driven by the need for adequate surveillance and hence 
organismal size, the idea that BAFF governs this parameter predicts that total 
systemic BAFF must be relatively constant and that the predominant source must 
be tied to organism volume. Indeed, bone marrow radiation chimeras revealed 
that a radioresistant, non-hematopoietic sources of BAFF fully supported primary 
B cell homeostasis (69).  More recent studies suggest that fibroblastic reticular 
cells are the primary source of system BAFF (70).  These observations 
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strengthen the idea that systemic BAFF levels are a surrogate for biological 
space, since BAFF is produced by cells whose numbers will scale with organism 
size.  Thus, BAFF depletion yields profoundly reduced TR, FO, and MZ B cell 
numbers, yet spares developing bone marrow B cell subsets. Further, the 
stringency of BCR-mediated selection among TR B cells is governed by BAFF; 
increasing BAFF lets TR B cells normally lost to negative selection survive (56, 
71, 72). Together, these observations favored the notion that systemic BAFF 
governs pre-immune B cell numbers by controlling TR cell throughput and 
mature B cell survival, thereby acting as the molecular surrogate for homeostatic 
‘space’ in the pre-immune B cell niche (68). 
1.3  Thymus dependent and independent B cell activation 
Among mature primary B cells, BCR ligation initiates downstream 
signaling systems that foster activation.  The type of antigen, the participating B 
cell subset, the avidity of BCR cross linking, and the intercellular interactions 
involved dictate the characteristics of the subsequent humoral immune response.  
In general, B cell responses follow the two signal paradigm (73), whereby BCR 
ligation (signal one) must be followed by additional activation and differentiation 
cues (signal 2) that are delivered via other cells or molecules.  Two broad 
categories of humoral responses are defined based on the source of second 
signals.  The thymus-dependent (TD) response involves second signals that are 
delivered when B cells internalize, process, and present protein antigens to CD4 
helper T cells.  In contrast, the second signals in thymus-independent (TI) 
responses are delivered through innate immune receptors such as TLRs 
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expressed by the B cells themselves (TI-1), or through exceptionally intense BCR 
cross linking alone (TI-2). 
Important differences between TD and TI responses include the naïve B 
cell populations that participate, the antibody isotypes generated, the response 
duration, the ultimate antibody affinity, and the extent of immunological memory 
established.  In general, B-2 cells, particularly those in the FO compartment, are 
the major contributors to TD responses.  In contrast, TI responses arise primarily 
from either B-1 cells or the B-2 lineage MZ subset (74).  These differences likely 
reflect the BCR signaling characteristics and differentiative potential of these 
pools, as well as the nature of inducing signals.  TI responses are of short 
duration and tend to be skewed towards IgM production, whereas TD responses 
are more protracted and will usually culminate in IgG.  Within days after TI 
antigen challenge, substantial numbers of antibody secreting plasma cells (PCs) 
appear in the splenic extrafollicular regions (75, 76).  The antibodies made by 
this extrafollicular response are largely IgM, and display comparatively low 
affinity for antigen.  Conversely, TD responses display a gradual but profound 
increase in average antibody affinity – a process termed affinity maturation (77).  
Moreover, both types of responses can generate relatively long-lived antibody 
forming cells and memory B cells (78-81).  As with TI responses, within days of 
TD antigen challenge, substantial numbers of PCs that generate low-affinity IgM 
appear in splenic extrafollicular regions.  However, a few days later clusters of 
proliferating B cells appear at the borders of B cell follicles and T cell zones in the 
lymph nodes and spleen (82, 83).  These are germinal centers (GCs), transient 
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structures wherein the unique functional features of TD responses emerge, 
including affinity maturation (84, 85), as well as efficient long-lived plasma cell 
generation (LLPC) (86). 
GC formation requires a series of cognate, bi-directional interactions 
between activated CD4 T cells and activated and antigen-presenting B cells 
beyond the initial T cell priming event with a dendritic cell (87, 88).  These include 
MHCII-restricted presentation by the B cell, costimulation via CD40-CD40L, and 
key cytokines.  Together, these interactions result in the adoption of a GC B cell 
transcriptional program driven largely by Bcl-6 (89-92).  A key gene upregulated 
in GC B cells is activation-induced deaminase (AID), which creates point 
mutations in Ig V regions (93, 94).  This so-called somatic hypermutation (SHM) 
mechanism results in clonal variants of GC B cells with altered antigen affinity 
and specificity (95).  Through selective competition and survival, clonal variants 
with higher affinity for antigen are preserved, whereas those with lower affinity 
are at a disadvantage and die (96).  While these processes are thought to occur 
most efficiently and frequently in GCs, affinity maturation and class-switch 
recombination (CSR) in extrafollicular sites have been reported (97, 98).  The 
details surrounding this preferential survival remain an area of intense 
investigation, but clearly involve competition for antigen and subsequently 
presenting said antigen (99).  Currently popular models posit that the 
anatomically defined GC light zones are where competition for antigen and T 
helper cell survival factors and instructive cues occur; whereas proliferation and 
AID-mediated SHM occur in GC dark zones (100).  Importantly, the CD4 helper T 
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cell subset responsible for proper GC reactions is transcriptionally and 
anatomically distinct from other T helper lineages (101).  As the moniker 
suggests, T follicular helper (TFH) cells migrate to the B cell follicle via CXCR5 
(102), select high affinity GC clones into effector pools via BLyS secretion (103) 
and direct immunoglobulin isotype determination. 
1.4 Activated B cells differentiate into discrete effector subsets 
 Circulating antibodies have biological half-lives in the range of days to 
weeks depending on heavy chain isotype; thus, long term protective immunity 
must rely on either LLPCs that persist indefinitely without seeding from BMEM 
(104-106), or upon the sustained generation of SLPCs from BMEM precursors 
driven by persistent antigen.  To adopt activated and effector fates, preimmune B 
cells must integrate instructional cues from a variety of signals, sustain the 
mutational stress of CSR and SHM, and undergo profound morphological 
changes to produce antibody. To support these functions, activated B cells 
undergo significant transcriptional reprogramming based on the cues they 
receive. Though initially thought to be required for PC commitment (107), the 
transcription factor BLIMP1 is necessary for bona fide PC differentiation (108).  
Given that PCs bear little morphological resemblance to their clonal progenitors, 
they are transcriptionally distinct because BLIMP1 extinguishes the B lineage 
determining transcription factor PAX5 (109, 110). In this regard, these cross 
competing transcription factors facilitate a gene expression program to direct 
mature B cells through activation, selection, and terminal effector function.  No 
master regulator of the BMEM cell lineage is yet identified; however, T-BET and 
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RORα associate with IgG2a/c and IgA isotypes, respectively, are indeed critical for 
the formation and maintenance of some BMEM subsets (111). 
The homeostatic regulation of antigen experienced B lineage pools is less 
well understood, and likely involves a more complex set of players than the 
comprehensive role assumed by BLyS for preimmune pools. Indeed, the 
heterogeneity in lifespan and composition of BMEM and PC subsets has only 
begun to be appreciated over the last several years, and will likely expand 
further.  For example, recent conceptual advances challenge the notion that PCs 
are a monolithic population.  Instead, T cell independent PCs are longer lived 
than previously thought (81); new subset markers have revealed phenotypic 
heterogeneity and complex turnover kinetics in BM PC pools (112, 113); and 
some PCs secrete cytokines and antimicrobial agents in addition to antibodies 
(114).  Despite this growing complexity, several factors that govern PC longevity 
and homeostasis have nonetheless been identified.  LLPC survival depends, at 
least in part, on BAFF and/or APRIL signaling via the BCMA and/or TACI 
receptors (115, 116).  In this regard, LLPCs are thought to occupy survival niches 
independent of the primary pool. Homing to and occupation of these longevity-
fostering niches is still an active area of research especially given newly 
discovered subsets and isotype-associated functional differences (117). 
 Similarly, several BMEM subsets have been defined, based on the 
presence of different isotypes and further markers (Table 1).  The immunological 
role of BMEM cells may appear ostensibly redundant with simultaneous, clonally 
similar, and elevated antibody titers; however, recent evidence highlights a 
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distinct BMEM cell role in response to pathogenic variants that have escaped the 
neutralizing capacity of the primary antibody response (118).  Moreover, 
delineating which BMEM subsets rapidly differentiate into PCs or engage in further 
GC formation upon secondary antigen challenge is an area of intense 
investigation.  While some evidence suggests that isotype determines BMEM cell 
subset and properties (119, 120), more recent work shows that surface markers 
such as PD-L2 and CD80 predict functional outcomes irrespective of isotype 
(121). Furthermore, the maintenance of these pools is independent of BAFF, 
antigen, or T cells (122-124).  In toto, these observations indicate that PCs and 
BMEM cells play non-redundant roles in immunity and occupy distinct homeostatic 
niches. 
1.5 Scope 
 The work presented herein describes the cytokine signals sufficient for the 
acquisition of a BMEM cell subset characterized by the expression of the 
transcription factor T-box Expressed in T cells (T-BET, encoded by the gene 
Tbx21).  In the first section, we describe how novel interactions between 
canonical TFH cell cytokines in concert with innate signals drive T-BET 
expression in the B lineage.  Further, since T-BET+ BMEM cells are phenotypically 
related to Age-associated B Cells (ABCs), we interrogated whether our model 
predicts age-related dysregulation of immune function in the second section. 
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2. IL-21 AND IL-4 RECIPROCALLY REGULATE T-BET IN B CELLS 
2.1 INTRODUCTION 
2.1.1 T-BET in immunity and B cells 
The transcription factor T-BET is part of an ancient family of 18 T-box 
transcription factors important for regulating many tissues and organs during 
metazoan development (125).  Although originally discovered in its role for TH1 
lineage commitment and optimal IFNγ production (126-128), T-BET expression 
arises in many immune cells and orchestrates cellular functions beyond specific 
cytokine production (129, 130).  Indeed, NK cell maturation and homeostasis, 
and proper CD4 T cell chemotaxis all require T-BET expression (131, 132).  
Thus, this transcription factor’s pleiotropic effects extend to a variety of immune 
cells.  B cell intrinsic T-BET expression fosters switching to IgG2a (111, 133-135), 
an isotype associated with both TH1-driven antibody responses and humoral 
autoimmunity (126, 136).  Moreover, T-BET is required for the generation of 
ABCs, which are transcriptionally distinct from other B cell subsets and have also 
been associated with both viral clearance and humoral autoimmunity (137-139).  
A more detailed introduction on ABCs is provided in chapter 3. 
Despite growing appreciation for the importance of T-BET-driven B cell 
fates, the exact signals that yield B lineage effectors characterized by T-BET 
expression – as well as how these regulate appropriate versus pathogenic 
outcomes – remain poorly defined.  Candidates include cell-intrinsic signals from 
adaptive and innate receptors, including the BCR and TLRs, as well as signals 
from TFH cells.  In this regard, several TH1 cytokines, including IL-12, IL-18, and 
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IFNγ, can induce T-BET in activated B cells (126, 136).  Nonetheless, the roles 
and interactions of canonical TFH cell cytokines – IL-21, IL-4, and IFNγ – in 
regulating T-BET expression have not been systematically interrogated (101, 
140, 141). 
2.1.2 Cytokines regulate B cell responses 
 Generally, intercellular communication occurs via cell-to-cell contact or 
secreted messengers.  The latter includes a loosely categorized group of small 
proteins called cytokines (~5-20kDa).  Importantly, these include interleukins, 
chemokines, tumor necrosis factors, and interferons but generally not hormones 
or growth factors (142).  Thus, depending on type of cytokine produced, cytokine-
secreting cells can regulate and instruct the behavior of other cells.  In this 
regard, TFH cells guide and direct B cell responses via the production of IFNγ, IL-
4, and IL-21.  Beyond their capacity in driving affinity maturation, TFH cells 
instruct isotype switching via these cytokines.  Indeed, the effects of IFNγ and IL-
4 on antibody isotype determination have been long appreciated (140, 141, 143-
145). However, in addition to the effects of the hallmark cytokine of the TFH 
lineage, IL-21 (146-149), how B cells integrate cytokine signals to achieve 
appropriate isotype and fate decisions remains unclear (150, 151).  Thus, careful 
consideration of each cytokine is necessary to understand its attributed effects 
on B cells. 
 While originally named for its capacity to promote antiviral activity in 
influenza virus infected chick embryos (152, 153), IFNγ-producing cells regulate 
a variety of cell-mediated immune responses.  Indeed, natural killer (NK), CD8, 
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and TH1 cells all produce IFNγ against intracellular pathogens and tumors (154).  
IFNγ functions by binding the IFNγR-α and -β chains, which drives JAK-induced 
phosphorylation of STAT1 (pSTAT1).  The resulting pSTAT1 homodimer 
translocates to the nucleus and initiates a change in gene expression (155).  For 
B cells, IFNγ drives CSR to the IgG2a/c and IgG3 isotypes (145, 156-158).  
Moreover, IFNγ receptor deficient mice fail to induce a normal intracellular 
pathogen IgG2a antibody response (159).  These observations lead to the 
presumption that TFH cell-derived IFNγ drives antiviral antibody responses; 
however, while global IFNγ is necessary for normal IgG2a responses, T cell 
derived IFNγ seems redundant in this capacity (140). Thus, while IFNγ is 
important for normal antibody responses against intracellular pathogens, the 
cellular source acting directly on B cells remains unclear. 
 In contrast to how IFNγ was discovered, IL-4’s immunological role was 
first shown by its direct action on B cells.  IL-4 signals by binding the IL-4Rα and 
IL-2 common-γ chain receptor, which drive JAK-mediated phosphorylation of 
STAT6 (pSTAT6).  The resulting homodimer translocates to the nucleus and 
drives transcription (160).  Two research groups independently discovered IL-4 
via its capacity to enhance B cell activation and drive CSR to IgG1 and IgE (161-
163).  Further, in vivo evidence also confirms and extends IL-4’s role in inducing 
these isotypes against extracellular pathogens (141, 143, 164); however, IL-4 is 
not critical for host survival against these infections. 
 In addition to the well-characterized roles of IFNγ and IL-4 in isotype 
determination, IL-21 also regulates B cell responses (165).  IL-21 functions by 
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binding the IL-21R and IL-2 common-γ chain receptor, which drives JAK-
mediated phosphorylation of STAT1, 3, 5a, 5b (pSTAT1, 3, 5a, 5b).  The 
resulting pSTAT homodimers and heterodimers (pSTAT1:pSTAT3) translocate to 
the nucleus and initiate gene expression changes (166).  While originally 
described for its role in NK cell expansion in vitro (167), subsequent serum 
isotype analysis revealed a critical role for in regulating IgG1 production (168).  In 
this regard, IL-21 was thought to account for the residual IgG1 observed in IL-4 or 
STAT6 deficient mice.  Moreover, subsequent reports demonstrated how IL-21 
induces the mutually antagonistic transcription factors BLIMP1 and BCL6, which 
are critical for B cell fate determination (169).  Indeed, given BCL6’s association 
with the GC B cell fate, in vivo evidence also confirms IL-21’s direct role in GC B 
cell maintenance presumably through BCL6 induction (150, 151).  Thus, IL-21 
regulates not only B cell fate decisions but also isotype determination. 
2.1.3 CD11c expression in B cells 
In addition to guiding cell fate decisions, cytokines also direct immune 
cells to cites of inflammation via the induction of chemokine receptors and 
integrins.  Indeed, IL-4, IFNγ, and IL-21 have all been shown to modulate 
expression of trafficking proteins (170-173).  Integrins are a family of 
heterodimeric cell adhesion receptors that mediate cellular migration, trafficking, 
and cell-to-cell contacts via binding to cell-surface or extracellular matric ligands.  
The heterodimers consist of α and β subunits.  CD11a, CD11b, CD11c, and 
CD11d are all α subunits that heterodimerize with the β2 subunit (CD18) (174, 
175).  Originally, CD11c was thought to demarcate DCs with high fidelity (176), 
 
 
 
 
18 
and thus later developed into a DC-ablative tool (177); however, it is now 
apparent that B and other cells normally express CD11c.  Thus, it is important to 
consider what this integrin does beyond its capacity to identify specific cell types.  
Functionally, CD11c facilitates efficient phagocytosis and cell mobility via its 
binding capacity of a variety of ligands including adhesion molecules (e.g. ICAMs 
and VCAMs), LPS, complement protein, and matrix proteins such as fibrinogen 
and collagen (175).  In accord with these capacities attributed to CD11c, deficient 
mice have compromised immune function.  Indeed, CD11c deficient mice are 
resistant to models of disease such as EAE and atherosclerosis and conversely 
mount reduced responses to pathogen challenge (178-181). In the B lineage, 
CD11c expression associates with viral or bacterial infections, autoimmunity, and 
neoplasia (138, 182-187), although its function is unclear.  Thus, the signals 
driving B cell intrinsic CD11c expression and the integrin’s role in normal or 
aberrant immune responses are of interest. 
2.1.4 Summary of findings 
Here, we show that B cells integrate IL-4, IL-21, and IFNγ signals to adopt 
distinct TBET+ effector fates.  In the context of TLR engagement, both IL-21 and 
IFNγ directly drive FO B cells to express T-BET in vitro.  However, IL-4 
antagonizes IL-21-driven TBET upregulation, but enhances IFNγ-induced T-BET 
expression.  Moreover, IL-21 but not IFNγ promotes CD11c expression.  
Consistent with these in vitro results, the in vivo frequencies of GC B cells and 
BMEM cells expressing T-BET or CD11c vary based on the prevailing cytokine 
milieu.  Finally, using viral and helminthic infections in single and double cytokine 
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KO mice, we show that the relative abundance of these cytokines governs 
whether GC and BMEM cells generated during ongoing immune responses 
express T-BET and CD11c.  Together, these findings reveal a previously 
unappreciated interplay between key TFH cytokines that, in concert with innate 
sensors, controls the adoption of T-BET+ fates among antigen-experienced B 
cells. 
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2.2 MATERIALS AND METHODS 
Mice 
Tbx21-/-, Stat6-/-, Tbx21f/fCd19Cre/+, C57BL/6, and BALB/c mice were maintained 
and used in accordance with the University of Pennsylvania Institutional Animal 
Care and Use Committee (IACUC) guidelines.  University of Pennsylvania 
IACUC approved all animal experiments.  Il4-/- mice were a gift from Dr. Paula 
Oliver.  Ifng-/- mice were a gift from Dr. Edward Behrens.  Il4-/-Ifng-/- double 
deficient mice were bred in house.  IL21r-/- and Il21Tg spleens and sera were 
shipped overnight on ice from Dr. Warren Leonard’s mouse colony at the NIH.  
All experimental mice were 2-6 months of age. 
Infections 
Mice were infected by oral gavage with 200 infectious larvae of 
Heligmosomoides polygyrus (HP), which were generated as previously described 
(188).  Mice were infected by intranasal (i.n.) infection with 30 TCID50 of influenza 
strain A/PR/8/34 (PR8) (ATCC).  Spleens and sera were harvested on days 
indicated in figure legends. 
In vitro cultures 
CD23+ splenic B cells were enriched by positive selection using MACS bead 
system (Miltenyi Biotec), labeled with either Violet Cell Trace (VCT, Invitrogen) or 
carboxyfluorescein succynimmidyl ester (CFSE, eBioscience) and were 
stimulated with 1uM ODN1826 (Invitrogen), 1ug/mL CLO97 (InvivoGen), F(ab)’2 
fragments of 10 µg/mL anti-IgM (Jackson ImmunoResearch Laboratories), 10 
µg/mL anti-CD40 (clone HM40-3; BL), 25 ng/mL IL21, 10 ng/mL IL4, 10 ng/mL 
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IFNγ (Shenandoah Biotechnology) at 37°C and 5.5% CO2 in RPMI supplemented 
with 10% characterized FBS (HyClone), 1% HEPES (Gibco), 1% glutamine 
(Invitrogen), 50 µM 2-mercaptoethanol (Gibco), 1% minimal essential amino 
acids (Gibco), and 1% OPI supplement (Sigma). 
Flow Cytometry 
Spleens were harvested at indicated days post immunization or infection, 
mashed between frosted glass slides, and filtered through 0.2 micron mesh. 
Antibodies or reagents reactive to the following antigens were purchased from 
BioLegend (BL), Beckton-Dickenson (BD), or eBioscience (eBio): T-BET (4B10, 
BL), CD11c (N418, BL), IgM (R6-60.2, BD), CD38 (90, eBio), CD138 (281-2, BL), 
IgD (11–26c.2a, BL), CD4 (RM4-5, BL), B220 (RA3-6B2, BL), CD62L (MEL-14, 
eBio), TCR-β (H57-597, BL), CD19 (6D5, BL), CXCR5 (L138D7, BL); PD-1 
(RMP1-30, BL); and PNA-FITC (Sigma), CD8 (53-6.7, eBio), CD4 (H129.19, BL), 
F4/80 (BM8, eBio), Ly-6G/GR1 (RB6-8C5, eBio). Exclusion based on Zombie 
Aqua (BL) positivity was used to identify live cells, and doublets were excluded 
by forward and side scatter height versus width analyses. Cells were analyzed on 
an LSRII or sorted on an Aria II (BD), and data analyzed using FlowJo software 
(Tree Star). Intracellular stains were performed using the eBioscience Foxp3 
transcription factor kit. 
Serum antibody titers and PR8-specific ELISA 
For ELISA, Immunosorb plates (Corning) were coated with 20 hemagglutination 
units (HAU) PR8 or 10 µg/ml anti-mouse heavy and light chain, and blocked with 
PBS containing 2% BSA. Virus used for coating ELISA plates was inactivated by 
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incubation with 0.1% beta-propiolactone (BPL; Sigma) and 0.1 M HEPES 
(Cellgro) overnight at 4C followed by a 90 minute incubation at 37C. Diluted sera 
were incubated for 1 hour at room temperature, detected with horseradish 
peroxidase conjugated goat anti–mouse IgG2a, IgG2b, IgG2c, or IgG1 antibodies 
(SouthernBiotech), and developed with using 3,3’, 5,5’ tetramethylbenzidine 
(TMB) substrate (BD). Color development was terminated with 2M H2SO4 then 
read on an EMax microplate reader (Molecular Devices) at 450nm. 
Quantitative PCR analysis 
RNA was extracted with the RNeasy kit (QIAGEN) and reverse transcribed using 
SuperScript II Reverse transcription (Invitrogen) according to the manufacturer’s 
protocols. cDNA was amplified using TaqMan Universal Master Mix (Applied 
Biosystems) and Taqman probes for various genes (Applied Biosystems). Real-
time PCR was performed with an ABI 7300 (Applied Biosystems). Relative 
expression (ΔΔCt) was calculated using Gapdh (Mm99999915_g1) expression as 
an endogenous control for cells that were FACS sorted ex vivo or stimulated in 
vitro. Probes: Il4 (Mm00445260_m1), Ifng (Mm00801778_m1), Il21 
(Mm00517640_m1), Tbx21 (Mm00450960_m1), Aicda (Mm00507774_m1). 
Transcriptional profiling and functional enrichment analysis 
After 20 hours in vitro stimulation as described above, RNA was isolated using 
the miRNeasy kit (Qiagen). Biotin-labeled complementary RNA (cRNA) was 
generated using the Illumina TotalPrep RNA amplification kit (Ambion). Illumina 
MouseRef-8 v2.0 expression Beadarrays were hybridized with cRNA. Scanned 
images were converted to raw expression using GenomeStudio v1.8 software 
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(Illumina). Data analysis was carried out using the statistical computing 
environment, R (v3.0.2). Differentially expressed genes (1.5-fold, FDR ≤ 0.05) 
were identified by linear modeling and Bayesian statistics using the Limma 
package (189). Clusters of co-regulated genes were identified by Pearson 
correlation using the hclust function of the stats package in R. Data have been 
deposited on the Gene Expression Omnibus (GEO) database for public access 
(Accession # GSE77145). 
Statistics 
Student’s t-test was used to generate all P-values, * P <0.05, ** P <0.01, *** P 
<0.001, **** P <0.0001.  All error bars are S.E.M. based on biological replicates. 
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2.3 RESULTS 
2.3.1 IL-21, IL-4, and IFNγ differentially regulate T-BET and CD11c 
expression 
In preliminary in vitro studies, we established that IL-21 drives TBET 
expression in FO B cells responding to TLR9, but neither BCR (α-IgM) nor CD40 
signals (Figure 1A).  To explore these interactions further, we cultured FO B 
cells with IL-4, IL-21, or IFNγ in the presence of TLR7 or TLR9 agonists.  Both 
Tbx21 transcripts and TBET protein increased markedly in FO B cells cultured 
with IL-21 or IFNγ (Figures 1B and C), but IL-4 influenced these outcomes 
differently.  IL-4 blocked IL-21-driven TBET upregulation, but enhanced IFNγ-
mediated TBET upregulation (Figures 1B and C).  Furthermore, IL-4 mediated 
these effects in a dose dependent manner when applied concomitantly with 
ODN1826 and IL-21 (Figure 1D). 
To determine whether IL-21 and IL-4 directly regulate TBET in B cells, 
either Il21r-/- or Stat6-/- B cells were co-cultured with wild type (WT) B cells and 
stimulated as above.  Since STAT6 is the key signal transducer of IL-4 and IL-
21R is required for IL-21 signaling (167, 190), we reasoned that co-culturing 
these mutants with WT cells would reveal any secondary trans effects of cytokine 
treatment.  In order to track cell type and expansion, WT or KO cells were 
labeled with VCT or CFSE, respectively (Figure 2A, top row).  While IL-21-
induced TBET expression in WT B cells, the co-cultured Il21r-/- B cells remained 
TBET negative, despite dividing to a similar extent.  Analogously, although IL-21-
driven TBET upregulation in WT B cells was reversed by IL-4, co-cultured Stat6-/-  
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Figure 1. IL-4 and IL-21 reciprocally regulate T-BET expression in vitro. All in 
vitro experiments used magnetically enriched CD23+ splenocytes (FO B cells). (A) 
WT or Cd19cre/+Tbx21f/f B cells were cultured with indicated stimuli for 48hrs and 
probed for T-BET (ΔMFI=WT-mutant). (B) Tbx21 Gene expression analysis (ΔΔCt) 
from WT B cells treated for 20hrs with indicated stimuli. (C) FO B cells treated as 
in (B) for 48h and probed for T-BET. ** P <0.01, *** P <0.001, n = 3 independent 
experiments. (D) WT FO B cells cultured with ODN1826 and IL-21 with IL-4 titra-
tion and probed for TBET. (B-C) Data are presented as means of biological repli-
cates ± SEM.
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splenocytes (FO B cells). (A and B) FO B cells from WT, Il21r-/-, or Stat6-/- spleens 
were labeled with either CFSE or Violet Cell Trace (VCT), treated with ODN1826 
and indicated cytokine combinations for 48h, and assessed for CD11c and T-BET. 
n = 3 independent experiments.
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cells were refractory to this negative regulatory effect (Figure 2A, bottom row). 
These results show that B cell intrinsic IL-21 and IL-4 signals directly and 
reciprocally regulate TBET expression in the context of TLR9 driven activation.  
Importantly, IFNγ treatment induced TBET irrespective of Il21r or Stat6 deficiency 
(Figure 2B).  The converse effects of IL-4 on IFNγ- vs IL-21-induced TBET 
expression suggests that unique, TBET-associated fates are likely facilitated by 
each cytokine.  We further interrogated this possibility in several ways.  First, 
since previous studies have linked TBET with CD11c expression (138), we asked 
whether IFNγ or IL-21 influence CD11c differently.  The results show that 
whereas IL-21 drives CD11c expression, IFNγ does not (Figure 2).  Further, 
similar to its effects on TBET, IL-4 blocks IL-21-induced CD11c expression.  
These findings indicate that IL-21 and IFNγ drive TBET expression through 
distinct mediators.  Further, TBET expression is not sufficient for the induction of 
CD11c.  Thus, TBET and CD11c are each directly but separately regulated by IL-
21 and IFNγ.   
To further interrogate the distinct TBET+ B cell fates driven by IL-21 versus 
IFNγ, as well as to distinguish TBET-dependent and -independent effects of each 
cytokine, we performed genome-wide transcriptional profiling on WT or Tbx21-/- B 
cells stimulated with either IFNγ or IL-21.  Principal components analysis shows 
that 82.7% of variance in these data was explained by the cytokine employed, 
while Tbx21 genotype accounted for 6.3% of the variance (Figure 3A).  Further, 
each cytokine induces a unique transcriptional profile, including some T-BET-
dependent shifts in gene expression (Figure 3B and Table I).  We confirmed that  
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Figure 3.    IL-21 drives T-BET-dependent shifts in gene expression distinct 
from IFNγ.  All in vitro experiments used magnetically enriched CD23+ spleno-
cytes (FO B cells). WT or Tbx21-/- FO B cells were cultured for 20h with IL-21 (21) 
or IFNγ (γ) with ODN1826, RNA was harvested, and principal component (A) and 
Z-score (B) analysis performed according to materials and methods. 
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diffSymbols diffEntrez IL21 IFNG IL21 IFNG
Hbb-bt 101488143 10.72 9.22 9.96 8.72
Pld4 104759 12.26 10.23 11.88 9.63
Csprs 114564 9.13 9.81 9.79 10.17
Adssl1 11565 10.19 8.76 9.56 8.38
Aicda 11628 10.62 8.16 9.57 8.16
Alas2 11656 8.70 8.70 8.17 8.08
Slc7a3 11989 9.58 11.94 10.89 12.33
Camk2b 12323 8.77 9.35 8.47 8.34
Cd86 12524 11.94 11.29 11.48 10.21
Cebpb 12608 9.80 10.40 10.26 11.03
Cxcr3 12766 8.59 8.89 7.96 8.02
Dapk2 13143 8.42 10.36 8.29 9.05
Ddx6 13209 10.43 10.85 11.02 11.22
Dmwd 13401 9.25 9.53 8.79 8.56
Igf2bp3 140488 9.90 9.52 9.19 8.80
Gcnt1 14537 10.30 9.69 10.42 10.28
Gfi1 14581 8.96 10.06 8.90 9.03
Slc6a9 14664 8.70 9.74 9.32 10.30
Gpr65 14744 10.08 9.98 9.66 9.18
Hba-a1 15122 12.98 12.81 11.08 10.61
Hhex 15242 12.03 11.50 11.87 10.90
Cxcl10 15945 8.07 11.26 8.05 9.70
Mrc1 17533 8.07 9.20 8.07 8.44
Enpp1 18605 8.96 10.10 9.03 9.44
Lgals3bp 19039 9.52 10.47 10.33 11.35
Sdc3 20970 8.69 8.48 9.34 9.22
Socs2 216233 8.25 9.21 8.31 8.39
Phf11a 219131 10.63 9.91 10.99 10.68
Trib3 228775 9.52 10.37 10.74 10.94
Oasl1 231655 8.69 9.41 9.08 10.03
Blvrb 233016 12.25 12.07 11.82 11.13
Rsad1 237926 8.98 9.49 8.36 8.71
Oas1g 23960 9.16 8.62 9.85 9.44
Usp18 24110 9.01 10.82 9.69 11.67
Ifnlr1 242700 8.45 10.02 8.60 10.64
Asns 27053 9.86 10.49 10.92 11.14
5031414D18Rik 271221 11.08 10.45 11.34 11.07
Abi2 329165 11.08 11.46 10.70 10.77
Tbx21 57765 10.68 12.07 8.29 8.51
Fkbp11 66120 9.11 9.92 8.93 9.26
Ifitm3 66141 9.95 10.52 10.39 11.68
Serpinb1a 66222 9.26 9.64 9.24 10.42
Sec11c 66286 10.14 10.37 9.88 9.74
Entpd4 67464 11.25 11.29 11.96 11.96
Chac1 69065 10.34 11.39 11.82 12.07
Tmem110 69179 10.22 10.43 10.07 9.67
Endod1 71946 11.34 10.31 11.42 10.96
Hvcn1 74096 12.52 11.50 12.40 10.68
Ly6k 76486 9.26 9.57 8.67 8.97
Lbh 77889 13.53 12.33 13.72 12.93
Table	II:	Top	50	differentially	expressed	genes.
Top	50	genes	differentially	expressed	according	to	stimulation	and	genotype		
generating	the	heatmap	in	Figure	3B.
WT Tbx21	KO
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Tbx21 expression was high in WT mice and low in KOs thus validating our 
dataset.  We find that IFNγ strongly and uniquely induced some genes, including 
Cxcl10 and Socs2, which were highly T-BET dependent.  Moreover, IL-21 also 
induced its own unique set of T-BET dependent genes including Aicda and Cd86.  
Additionally, there are some T-BET sensitive genes, such as Cxcr3, that were 
induced by both cytokines.  Lastly, in accord with T-BET’s role as a 
transcriptional repressor (191, 192), we also found some genes that were 
potently induced in the absence of T-BET such as Trib3, Csprs, and Slc7a3.  
Thus, although IFNγ and IL-21 overlap in regulating some T-BET dependent 
genes, each drives a unique transcriptional profile. 
 2.3.2 Relative abundance of IL-21, IL-4, and IFNγ regulate T-BET 
expression in vivo 
Our in vitro findings suggest that IFNγ, IL4, and IL21 interact to modulate 
TBET and CD11c expression in B cells.  As an initial assessment of whether this 
relationship exists in vivo, we surveyed GC B and BMEM cells for TBET 
expression in C57BL/6 (B6) versus BALB/c mice (Figure 4A), because these 
strains display inherent TH1 versus TH2 skewing, respectively (193).  We 
reasoned that if TBET expression is promoted by milieus rich in IFNγ, but 
repressed in those with plentiful IL-4 and little IFNγ, then the frequencies of 
TBET+ B cells in these two strains should differ. In agreement with this prediction, 
most GC B cells in B6 mice are TBET+ (Figure 4B), and variable CD11c 
expression was restricted to BMEM cells (Figure 4C).  In contrast, BALB/c mice 
lack TBET+ B cells (Figure 4B), despite a small cohort of TBET-CD11c+ BMEM  
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C57BL/6 (B6) or BALB/c GC B cells and (C) T-BET and CD11c on BMEM cells. n = 
3 experiments. 
 
 
 
 
32 
cells (Figure 4C).  These findings are consistent with the notion that IFNγ and IL-
4 levels regulate TBET expression in GC B cells.  To probe the impact of IL-21 
on this overall relationship, we next asked whether extra-physiological levels of 
IL-21 would foster accumulation of TBET+CD11c+ B cells.  Although the partially 
activated state of B cells in these mice confounds conventional phenotyping 
strategies (Figure 5A), nearly all mature B cells in Il21-Tg bear a CD23-CD21- 
phenotype identical to the TBET-dependent ABC subset (169, 194).  
Furthermore, surface IgD and IgM expression on B-2 B cells reveals that excess 
IL21 does not drive profound switching to other isotypes (Figure 5A, far right).  
Regardless, profound increases in both TBET and CD11c expression were seen 
in all splenic B-2 B cells in Il21-Tg mice (Figure 5B), which is consistent with our 
in vitro results suggesting that IL-21 drives both TBET and CD11c expression.  
Furthermore, analysis of antigen-experience subsets indicates that 
TBET+CD11c+ accumulate in many different activated B cell subsets (Figures 
6A&B).  Finally, consistent with TBET’s role in fostering class switch 
recombination to IgG2a/c, we observed a marked increase of IgG2a/c but not IgG1 
serum antibody titers in Il21-Tg compared to WT mice (Figure 5C). 
Together, our in vitro and in vivo observations prompt a model in which 
the relative availability of IL-4, IL-21, and IFNγ govern the likelihood of 
establishing BMEM cells expressing TBET and CD11c.  Further, they suggest that 
abundant IFNγ will drive a TBET+CD11c- B cell fate regardless of IL-4 or IL-21 
levels, but that in the absence of IFNγ, the TBET+CD11c+ fate will be reciprocally 
regulated by IL-21 versus IL-4.  We therefore evaluated these predictions by  
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tracking the immune responses to either influenza virus or H. polygyrus infections 
in mice where cytokine availability could be experimentally manipulated. 
2.3.3 Influenza virus infection generates T-BET+CD11c+ BMEM in the absence 
of IL-4 and IFNγ 
Influenza virus infection results in a well-characterized T-dependent and 
TH1-skewed response, in which responding TFH cells produce copious IFNγ as 
well as IL-21 and IL-4 (140).  Thus, we reasoned that IFNγ would induce T-BET 
expression in GC B and BMEM cells, but in the absence of IFNγ, IL-4 would 
prevent TBET expression.  Accordingly, WT or Ifng-/- mice were infected with the 
A/Puerto Rico/8/1934 H1N1 influenza virus strain (PR8).  As expected, WT 
animals mounted a robust GC B cell response to PR8 (Figure 7A), and these 
GC B cells expressed T-BET (Figure 7B).  In contrast, GC B cells in Ifng-/- mice 
failed to express T-BET (Figure 7B) even though the magnitude of the GC B cell 
response was similar to WT (Figures 7A&C).  Although the splenic PC numbers 
were reduced in Ifng-/- mice, BMEM cell numbers remained intact across 
genotypes (Figures 7D & 7E).  Thus, although the magnitude of the response 
varied slightly across gentoypes, all infected mice mounted a response above 
non-infected controls. 
To confirm the intracellular T-BET staining and assess the cytokine profile 
of TFH cells, we sorted both GC B cells and TFH cells from each genotype (Figure 
8A). Indeed, gene expression of Tbx21 from FACS sorted GC B cells in WT and 
Ifng-/- mice confirmed our intracellular T-BET stain (Figure 8B).  Next, we 
confirmed that FACS sorted TFH cells from WT and Ifng-/- mice expressed equal  
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levels of Il4 and Il21 transcripts (Figures 8C & D).  Moreover, although reduced 
in magnitude, Ifng-/- mice mounted a comparable TFH cell response to WT 
controls (Figure 8E).  These results are consistent with the idea that in the 
absence of IFNγ, IL-4 blocks T-BET expression in response to IL-21.  To directly 
test this, we infected Il4-/-Ifng-/- double deficient mice with PR8.  While Il4-/-Ifng-/- 
mice mounted a blunted GC B cell response (Figures 7A&C), these cells 
nonetheless clearly expressed T-BET (Figures 7B & 8B).  Furthermore, only the 
GC B cell response was blunted in Il4-/-Ifng-/- mice (Figure 7C), whereas the PC 
and BMEM were comparable to WT (Figures 7D&E).  Lastly, Il4-/-Ifng-/- mice 
mounted a comparable TFH cell response with the same levels of Il21 transcripts 
as WT (Figures 8D&E). 
We next assessed BMEM cells for T-BET and CD11c expression and 
probed the serum for IgG2c or IgG1 PR8-reactive antibody given our initial 
phenotypic studies (Figures 4C & 5C).  The composition of the BMEM cell pool 
differed according to genotype in response to infection (Figures 9A&B).  While 
WT mice generated some T-BET+CD11c+ BMEM cells, Ifng-/- mice produced 
almost none above non-infected controls, suggesting the dominance of IL-4 in 
the absence of IFNγ.  Lastly, Il4-/-Ifng-/- mice produced the most TBET+CD11c+ 
BMEM cells, presumably reflecting IL-21 activity in the absence of any repressive 
IL-4 effects.  Furthermore, we assessed PR8 reactive serum antibody titers of the 
IgG2c and IgG1 isotypes and asked whether they correlated with T-BET 
expression.  Consistent with the role of IgG2c in antiviral immunity (195, 196), WT 
mice produced the most PR8-reactive IgG2c compared to Ifng-/- and Il4-/-Ifng-/-  
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mice (Figure 9C).  Importantly, a substantial amount of antigen specific IgG2c is 
independent of both IFNγ and B cell intrinsic T-BET expression.  Lastly, PR8-
reactive IgG1 was most prominent in Ifng-/- mice, which is consistent with an IL-4 
dominant response.  Overall, these findings confirm and extend our in vitro 
findings, since the same interplay of cytokines directs T-BET expression among 
B effectors in vivo.  Further, our observations suggest that T-BET+CD11c+ BMEM 
cells will be fostered in immune responses where IL-4 and IFNγ are limited. 
2.3.4 Il-4 deficiency is sufficient to induce T-BET+CD11c+ BMEM 
independently of IFNγ in Heligmosomoides polygyrus infection 
Results with influenza virus infection are consistent with the notion that 
IFNγ drives T-BET expression irrespective of concomitant IL-4 or IL-21, and that 
eliminating IFNγ  creates a situation where the relative levels of IL-4 and IL-21 
govern the T-BET+CD11c+ phenotype.  However, this subtractive approach does 
not necessarily show that in responses where IFNγ is normally absent, the sole 
determinant of a T-BET+ fate is IL-4 availability.  Accordingly, we asked whether 
IL- deficiency is sufficient to permit T-BET expression in GC B cells during a TH2 
response, using Heligmosomoides polygyrus (HP).  This intestinal helminth 
induces IL-4 and IL-21 production by TFH cells, which drives a robust IgG1 
response (141).  Thus, we hypothesized that in the absence of IL-4, IL-21 would 
be sufficient to induce T-BET expression in B effectors.  To test this idea, we 
infected WT or Il4-/- mice with HP, and probed GC B cells for T-BET.  As 
expected, WT mice mounted a GC B cell response that lacked T-BET expression 
(Figures 10A-C).  Conversely, although blunted in magnitude, Il4-/- mice initiated  
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Figure 10. Heligmosomoides polygyrus (HP) infection drives T-BET+ GC B 
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a TBET+ GC B cell response.  To eliminate the possibility that excess IFNγ in Il4-/- 
mice explains these phenotypes, we infected Il4-/-Ifng-/- mice with HP.  The GC B 
cell response in Il4-/-Ifng-/- mice was restored to WT levels (Figure 10C) but 
maintained T-BET expression independently of IFNγ (Figure 10B).  Importantly, 
the magnitude of the PC and BMEM cell response remained intact across 
genotypes (Figures 10D&E).   
To confirm the intracellular T-BET staining and assess TFH cell cytokine 
profile, we sorted both GC B and TFH cells from each genotype (Figure 11A).  
Tbx21 gene expression from FACS sorted GC B cells in WT, Ifng-/-, and Il4-/-Ifng-/- 
mice confirmed the intracellular T-BET stain (Figure 11B).  Further, TFH cells 
from both Il4-/- and Il4-/-Ifng-/- mice produced less Il21 even though these mice 
generated comparable or more TFH cells than WT (Figures 11C&D).  Finally, we 
again assessed BMEM cells for TBET and CD11c expression and probed the 
serum for serum IgG2c or IgG1.  We observed a similar alteration in the BMEM pool 
according to cytokine availability. Whereas HP-infected WT mice did not 
generate T-BET+CD11c+ BMEM cells, both Il4-/- and Il4-/-Ifng-/- mice did—again 
suggesting an IL-21-driven phenotype independent of IFNγ (Figures 12A&B).  
Isotype representation varied with T-BET expression: whereas WT mice 
produced >95% IgG1, over half of the serum antibodies in Il4-/-Ifng-/- and Il4-/- mice 
were IgG2b and IgG2c (Figure 10C).  Overall, the HP infection data are consistent 
with our model inasmuch as in the absence of IFNγ production, we observe T-
BET and CD11c expression that is sensitive to IL-4.  Moreover, the consistent 
relationship of these cytokines to T-BET and CD11c expression in both types of 
 
 
 
 
43 
infection suggest a common feature to most humoral immune responses. 
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Figure 11. TFH cells in Heligmosomoides polygyrus (HP) infection produce 
IL-21.  All figures based on FACS stained splenocytes and sera from non-infected 
or day 14 post oral gavage of 200 HP in WT  (n=20), Il4-/- (n=22), and Il4-/-Ifng-/- 
(n=11) mice across 3-6 experiments with ≥3 mice per group, * P <0.05, ** P <0.01, 
**** P <0.0001. (A) Representative sort strategy for GC B and TFH cells.  Gene 
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Figure 12. Heligmosomoides polygyrus (HP) infection drives T-BET+CD11c+ 
BMEM cell formation in the absence of IFNγ and IL-4.   All figures based on FACS 
stained splenocytes and sera from non-infected or day 14 post oral gavage of 200 
HP in WT  (n=20), Il4-/- (n=22), and Il4-/-Ifng-/- (n=11) mice across 3-6 experiments 
with ≥3 mice per group, ** P <0.01, **** P <0.0001. (A) Representative FACS stain-
ing for T-BET and CD11c on BMEM cells as defined in Figure 10. (B) Enumeration of 
T-BET+CD11c+ BMEM cells.  (C) Total serum IgG1 and IgG2c + IgG2b titers.
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2.4 DISCUSSION 
Together, these results show that in the context of TLR7 or TLR9 
engagement, the aggregate of IFNγ, IL-21, and IL-4 signals determines whether 
B cells adopt a T-BET+ fate.  We provide in vitro evidence for a novel route to T-
BET induction via the hallmark TFH cell cytokine, IL-21.  Importantly, this occurs 
robustly in the context of TLR engagement and independent of antigen receptor 
engagement or costimulation.  Furthermore, concomitant IL-4 signals antagonize 
IL-21-induced T-BET expression but enhance IFNγ-driven T-BET.  Moreover, IL-
21, but not IFNγ, promotes CD11c expression independent of T-BET.  Using 
influenza virus and H. polygyrus infections, we show that these interactions 
function in vivo to determine whether T-BET+ and CD11c+ B cells are formed. 
These findings suggest that T-BET+ B cells seen in health and disease share the 
common initiating features of TLR driven activation within this circumscribed 
cytokine milieu. 
TLR engagement appears necessary to position activated B cells for these 
fates upon subsequent IL-21 signaling.  We have obtained similar results with the 
TLR2/4 ligand LPS (Figure 13A), suggesting pathways common to most TLRs, 
and perhaps other innate receptors, provide these key initial signals.  We 
speculate that these innate signals alter gene loci accessibility for subsequent 
TFH cytokine cues since there are reports of crosstalk between the TLR-MyD88 
and IL-21r-STAT3 pathways in B cells (197, 198).  Indeed, prior reports that 
CD11c+ or TBET+ B cells emerge in responses to a variety of viral and bacterial 
infections are consistent with this idea (137, 183).  Furthermore, while BCR and  
 
 
 
 
47 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 13. Dominant IFNγ-driven T-BET expression.   All in vitro experiments 
used magnetically enriched CD23+ splenocytes (FO B cells).  FO B cells treated 
with LPS (A) or ODN1826 (B&C) and indicated cytokine combinations for 48h, and 
assessed for T-BET and CD11c.  n = 3 independent experiments.
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CD40 engagement do not induce T-BET with IL-21, these signals do consistently 
down-modulate the levels of T-BET expression induced by ODN1826 and IL-21 
(Figure 1A).  This further suggests complexity among the NF-κB, STAT, and 
MyD88 signal cascades.  Thus, understanding how B cells integrate these 
disparate signal transduction events should elucidate effector cell fate decisions. 
The differential effects of IL4 on IL21 versus IFNγ suggest a complex 
interplay of STAT-dependent transcriptional regulation.  The clear dose-response 
relationship of IL4-mediated effects is consistent with the idea that competitive 
relationships are involved (Figure 1D).  Furthermore, IL-21-driven T-BET 
remains sensitive to IL-4 signals even 20 hours after it is induced (Figure 13B).  
This suggests that IL-21-induced T-BET fates are plastic in vitro and still subject 
to the repressive activity of IL-4.  Although IL-4Rα and IL-21R both require 
common-γ chain receptor to phosphorylate their associated STATs (199), our 
Stat6-/- coculture data indicate that competition for membrane proximal receptor 
components is unlikely to explain these findings (Figure 2).  If this were the case, 
then Stat6-/- cells would also be subject to IL4’s repressive effects.  Instead, 
downstream events are more likely candidates, including differential occupation 
of transcriptional regulatory sites, and altered stoichiometric relationships among 
the JAK-STAT proteins involved.  In T cells, it is established that IL-21 can drive 
T-BET in a STAT1 dependent manner (200, 201); however, IL-21 transduced 
signals have not been so carefully characterized in the B lineage.  Thus, 
assessing whether IL-21-driven pSTAT1 or pSTAT3 is altered by IL-4 or whether 
STAT6 binds the Tbx21 locus could elucidate the mechanism behind the 
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interplay of IL-21 and IL-4 on T-BET expression. 
The preferential induction of CD11c and differential effects of IL-4 
stimulation lead us to the conclusion that IL-21 and IFNγ drive distinct T-BET+ 
fates.  Thus, since T-BET is a transcription factor, we explored how these two T-
BET inducing stimuli differed in terms of gene expression in the presence or 
absence of T-BET (Figure 3).  The most striking difference was between 
cytokine treatments as measured by principal component analysis (Figure 3A).  
However, each cytokine treatment induces and represses overlapping and 
distinct sets of genes in a T-BET dependent manner (Figure 3B).  Specifically, in 
accord with its role in GC maintenance, IL-21 induced Aicda and Cd86, which are 
both critical for SHM and CSR (93, 202).  Consistent with prior reports showing 
IL-21 driven Aicda and Cd86 expression, and we further show that IL-21 induced 
Aicda and Cd86 expression depends on T-BET (203, 204).  Overall, IL-21 drives 
a gene expression profile most consistent with that of the GC B cell fate.  
Although overlap exists, the T-BET-dependent induction of Cxcl10 by IFNγ and 
not IL-21 further confirms the notion that these two stimuli are distinct.  Lastly, 
each cytokine represses a set of genes in a T-BET dependent manner.  Although 
currently most of these genes have poorly defined immunological roles, Trib3 has 
been shown to directly bind and disrupt to Akt kinase activity suggesting it may 
have a role in nutrient sensing.  Overall, these transcriptional analyses further 
confirm that IFNγ and IL-21 drive distinct T-BET+ fates. 
Our findings reveal a TFH cytokine network that governs T-BET+ B cell fate 
decisions in the context of TLR stimulation.  In accord with pervious reports, IFNγ 
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drives T-BET expression and is not appreciably influenced by the presence of 
either IL-4 or IL-21 (Figure 13C).  Conversely, in the absence of IFNγ, IL-4 and 
IL-21 reciprocally regulate T-BET and CD11c expression both in vitro and in vivo.  
Since immune responses are rarely monolithic with regard to these three 
cytokines (140, 205), we suggest that the resulting multifunctional TFH cells can 
generate a diverse set of B effectors.  Consequently, altering the cytokine milieu 
affects the isotypes generated (Figures 9C&D and 12C) and the composition of 
the BMEM pools (Figure 9A&B and 12A&B) while largely maintaining the 
magnitude of the response.  Since T-BET+CD11c+ B cells are observed in 
autoimmunity, viral infections, and aging, it is tempting to speculate that an 
underlying common feature is endosomal TLR engagement coupled with either 
copious IFNγ or abundant IL-21 with little IL-4.  Indeed, both TLR7 and IL-21 
deficiencies ameliorate disease in humoral autoimmunity models (206-209), and 
poor IL-4 production has been observed in TFH from aged mice (210).  Thus, 
understanding this interplay among IL-4, IL-21, and IFNγ might better define the 
etiology of humoral autoimmunity where ABC-like cells are observed (138, 187, 
211, 212). 
While it is clear that IFNγ and IL-21 differentially induce CD11c expression 
(Figure 2), the functional consequences of expressing this integrin remain 
elusive.  Importantly, the restriction of CD11c expression to BMEM cells is 
consistent with prior BMEM subsetting studies in human tonsils and may thus 
define a tissue-homing population (185).  While CD11c expression per se does 
not define tissue residency, future studies should assess whether altered integrin 
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and chemokine expression occurs on BMEM cells generated in skewed cytokine 
milieus.  Indeed, TFH cells have been reported to produce every individual and 
combinatorial permutation of IL-4, IL-21, and IFNγ (140, 205).  Thus, since a 
normal humoral immune response generates various pools of cytokine-skewed 
TFH cells, they consequently drive a diverse array of B cell effectors.  This 
assortment of effectors may be beneficial to host protection because adopting a 
singular strategy of immunity may be deleterious for the organism. 
Finally, the most prominent B cell role, Ig production, is significantly 
affected in our infection models.  In accord with previous reports, we observe that 
B cell intrinsic TBET expression during PR8 infection correlates with IgG2c 
production in WT mice (111).  However, even though Ifng-/- mice did not express 
TBET in B cells (Figures 7B and 8B), they produced as much PR8-reactive 
IgG2c antibody as Il4-/-Ifng-/- (Figure 9C) where prominent T-BET expression was 
observed.  Thus, a substantial amount of IgG2c is both IFNγ and T-BET 
independent.  These observations are consistent with a prior report showing that 
TI-generated IgG2c is T-BET-dependent whereas IgG2c from TD responses is not 
(133).  If the remaining IgG2c PR8-reactive antibodies detected in Ifng-/- or Il4-/-
Ifng-/- mice are solely a result of a TD response, then the BMEM clones and PR8 
anti-sera in these mice should be of higher affinity than their WT counterparts.  
Although the HP infection experiments match current dogma regarding TBET 
expression and IgG2c production (Figure 12C), these data also suggest that IL-
21 can drive IgG2c production independently of IFNγ.  Again, how IFNγ and IL-21 
drive different but related cell fates remains unclear but could reflect an 
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extrafollicular versus GC response.  Overall, these studies expose a thus far 
poorly understood pathway to IgG2c switching involving IL-21 and some 
transcriptional switch factor.  Given role of IgG2c autoinflammatory diseases 
(213), exploring how this pathway leads to IgG2c production could underscore the 
etiology of some humoral autoimmune diseases. 
Together, our in vitro and in vivo observations prompt a model in which 
the relative availability of IL-4, IL-21, and IFNγ govern the likelihood of 
establishing BMEM cells expressing T-BET and CD11c.  Further, they suggest that 
abundant IFNγ will drive a T-BET+CD11c- B cell fate regardless of IL-4 or IL-21 
levels, but that in the absence of IFNγ, the T-BET+CD11c+ fate will be 
reciprocally regulated by IL-21 versus IL-4 (Figure 14).  Further, although both 
IFNγ and IL-21 induce TBET expression, IFNγ blunts IL-21-driven CD11c 
expression (Figure 13C).  This reinforces the notion that IFNγ-induced TBET is 
refractory to the concomitant IL-4 or IL-21 signals, and therefore it is the 
dominant of the three cytokines for TBET induction. 
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Figure 14. Model of IL-4, IL-21, and IFNγ interplay on T-BET expression.  
IL-21 uniquely induces both T-BET and CD11c expression.  IL-4 blocks the capacity 
of IL-21 to drive TBET and CD11c expression but enhances the ability of IFNγ to 
induce T-BET.   IFNγ either actively blocks IL-21-induced CD11c expression or 
dominantly drives T-BET expression alone.
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3. ABCs IN PROTECTIVE AND AUTOREACTIVE RESPONSES 
3.1 INTRODUCTION 
3.1.1 Dysregulation of the immune system associates with age 
Advancing age is accompanied by far-reaching shifts in immune system 
development and function, including reduced lymphopoiesis (214-217), blunted 
primary and recall immune responses (218-233), the appearance of 
autoantibodies (234-239), and increased frequencies of autoimmune and 
autoinflammatory conditions (240). Accordingly, shifts in the generation and 
relative representation of lymphocyte subsets have been scrutinized as potential 
mechanisms underlying these features. Within the T lymphocyte lineage, thymic 
involution, reduced T lineage specification, and an inversion in the ratio of naïve 
to memory T lymphocytes are established age-associated phenomena (215, 228, 
236, 241-247), and more recent studies have linked these shifts to compromised 
vaccine and disease responses.  Within the B lineage, similar reductions in early 
lineage specification and shifts in the sizes and kinetics of developing B cell 
pools have also been appreciated for some time (214, 216, 217, 222, 224, 226, 
248-253).  However, despite numerous clues indicating changes in the functional 
attributes of peripheral B cells with age (222, 223, 235, 252, 254-257), whether 
shifts in pre-immune and antigen experienced B cell subsets occur with age, as 
well as the functional consequences of such changes, remained unclear until 
recently. Within this context, a B cell subset with unique functional properties was 
identified and characterized. 
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3.1.2 ABCs emerge with age and have a unique surface marker phenotype 
ABCs were first described in simultaneous reports from Hao et al and 
Rubstov et al, using distinct but largely complimentary phenotypic and functional 
criteria (194, 258) (reviewed in (259)).  As their name implies, the ABC pool 
emerges in mid-life and continuously enlarges with advancing age.  Thus, in 
healthy adult mice, ABCs are either absent or comprise a negligible proportion of 
peripheral B cells until about 12 months of age, then increase steadily in both 
proportion and number (194, 258-260).  ABCs are observed in multiple inbred 
strains and F1 combinations, suggesting they are a common feature of the aging 
B cell pool (194).  Although the tempo with which ABCs emerge varies 
considerably among individuals, they generally comprise 30-40% of mature 
recirculating B cells by 24-30 months of age (260).  Moreover, ABCs tend to 
appear sooner and achieve higher numbers and representation in females (258), 
although the exact basis for this sex-associated dichotomy is unclear [discussed 
in (259)].   
ABCs display a distinct surface phenotype in mice (Table I).  They are 
mature B cells, as evidenced by their lack of CD93.  Further, while positive for 
both B220 and CD19, they lack the canonical FO, MZ or B1 B cell markers 
CD23, CD21 and CD43, respectively.  Detailed phenotypic, functional, and 
transcriptional analyses confirmed that ABCs differ from all previously defined B 
cell subsets.  Whereas Hao et al (194) used this combination of features to 
define the population, Rubtsov et al (258) employed CD11c as a singularly 
characteristic marker.  Thus, while the B cell population circumscribed by the 
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criteria in Hao et al includes the CD11c+ cells of Rubtsov et al, it also captures 
additional cells that lack CD11c.  This distinction may underlie some apparent 
differences in functional attributes. 
Anatomically, ABCs are found in the blood, spleen, and BM, but are rarely 
observed in lymph nodes (194). While these qualities suggest they are circulating 
cells, multiple observations suggest their trafficking and homing patters differ 
from FO B cells and other recirculating subsets.  For example, expression of the 
follicle homing factor CXCR5 is reduced on ABCs (194), and more recent studies 
reveal they are enriched at the splenic T:B border, presumably reflecting 
migratory differences imparted by increased CCR7 expression (261). Based on 
these observations, it is tempting to speculate that ABCs may be involved in the 
age-associated alterations in MZ composition previously reported by Birjandi et al 
(262).  Further, based upon their absence from the lymphatics, coupled with the 
lack of formal studies probing their circulatory properties, it remains possible that 
some ABCs are sessile tissue resident cells.  In this regard, further phenotypic 
analysis of ABCs may reveal their origins and function in health and disease. 
3.1.3 ABC activation and survival requirements differ from those of other B 
cell subsets 
In addition to their distinct phenotype and localization characteristics, 
ABCs display unique activation requisites and functional attributes. Initial in vitro 
studies revealed that, unlike TR, FO, or MZ B cells, ABCs fail to proliferate after 
BCR cross-linking, but nonetheless survive (194).  In contrast, they exhibit robust 
proliferative responses to stimulation via TLR9 or TLR7, and despite being 
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refractory to BCR cross-linking alone, concomitant BCR engagement potentiates 
their proliferative responses to TLR ligands (194, 258).  Consistent with these 
observations, both TLR9 and TLR7 expression are elevated in ABCs (194). 
There is probably heterogeneity among ABCs in terms of relative responsiveness 
to TLR7 versus TLR9 ligation; cells included by the surface marker criteria of Hao 
et al show more extensive proliferation to TLR9 than to TL7 agonists, whereas 
cells defined by the criteria of Rubtsov et al display the reverse.  Whether this 
reflects alternative routes of generation, different stages of the ABC 
differentiation pathway, or other distinctions remains unclear. 
ABCs are unusual – and again unlike other B cell subsets - because they 
express both the BR3 and TACI receptors for BLyS but are independent of BLyS 
for their survival (194). Thus, BLyS neutralization in vivo spares ABCs, despite 
eliminating all FO and MZ B cells. Because ABCs display the same spectrum of 
BLyS receptors as FO and MZ B cells, they bind and sequester BLyS 
equivalently and can act as super-competitors for this limiting cytokine, inasmuch 
as they consume BLyS but do not need it to survive.  Accordingly, as ABCs are 
generated and accumulate, they capture a progressively larger proportion of the 
BLyS-dependent niche at the expense of the FO compartment.  Moreover, this 
capacity for BLyS-independent survival capacity is similar to what has been 
reported for Bmem cells, although currently defined Bmem pools do not express 
BR3 (263).  Given the recent advances in delineating murine Bmem cell subsets 
(121, 264), exploring potential heterogeneity within the ABC pool may elucidate 
how ABCs fit into the broader immunological context. 
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3.1.4 ABCs exhibit a characteristic set of effector attributes  
The unique functional attributes of ABCs extend to virtually all B cell 
effector mechanisms, including antigen presentation, cytokine secretion, kinetics 
of PC differentiation, and isotype switching preferences.  Several studies have 
established that ABCs are effective APCs.  Initial findings in vitro indicated that 
ABCs can serve as APCs, in accord with their comparatively high levels of MHC 
II, CD80, and CD86 (194).  Further, ABC-mediated antigen presentation in vitro 
tends to skew naïve CD4 T cells to a TH17 fate, although this was not exclusive 
of other CD4 T cell cytokine profiles (194).  More recent findings indicate that 
ABCs are also potent APCs in vivo (261).  When activated by either TLR7 or 
TLR9 agonists, ABCs secrete a variety of cytokines, including IFNγ, IL-4, IL-6, 
and IL-10.  Finally, upon activation, ABCs rapidly differentiate to antibody 
secreting PCs and tend towards IgG2a/c class switching (137, 261), despite their 
broad surface IgM and IgD expression (194).  Given their propensity to become 
antibody-secreting cells, ABCs may constitute a population of slowly 
accumulating Bmem cells generated in response to nucleic acid containing 
antigens.  While it is unclear whether isotype or costimulatory molecule 
expression governs Bmem cell responses (119-121), most ABCs are unswitched 
and remain uncharacterized for PD-L2 and CD73 expression.  Lastly, ABCs also 
express CD95 and CD138 based on microarray analysis (258), which are 
markers associated with the GC and PC cell fates respectively (see Table 1).  
Further characterization should distinguish the possibility of distinct ABC subsets 
or an atypical state of activation.  In toto, ABCs effector mechanisms seem to be 
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largely normal, although skewed toward a type-I response. 
3.1.5 ABCs are generated in response to intracellular infections 
Early adoptive transfer studies revealed that FO B cells give rise to ABCs.  
In these studies, CFSE labeled FO B cells were transferred to congenic hosts 
and harvested 30 days afterwards, revealing that transferred cells which had 
extensively proliferated had acquired the ABC phenotype (194).  This 
observation linked the generation of ABCs with extensive division, although the 
stimulating conditions driving the phenotype were unclear, and further functional 
characterization of these recently formed ABCs was hampered by the small cell 
numbers recovered in such experiments.  Nonetheless, these findings suggest 
that ABCs are likely an antigen-experienced pool.  Since B cell responses 
against viruses result in a protective, T-BET dependent IgG2a/c response, it was 
hypothesized that a viral infection would drive T-BET in vivo. Indeed, mice 
infected with gamma herpes virus, vaccinia, or LCMV all produced T-
BET+CD11c+ B cells (137).  Of the TLR agonists used, TLR7 stimulation is the 
most effective at driving T-BET expression in the context of BCR and IFNγ 
stimulation.  Lastly, B cell intrinsic T-BET expression played a non-redundant role 
in controlling viral and anti-viral IgG2a/c production.  These findings have been 
extended to human studies where a subset of B cells in HIV-viremic individuals 
also display an ABC surface phenotype but are yet to be fully characterized for T-
BET and CD11c (265).  In toto, these data support the notion that ABCs are 
indeed antigen experience cells arising from immune responses characterized by 
nucleic acid containing antigens in the context of proinflammatory cytokines.  
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Given the similar nature of the antigens, nucleic acid containing self-antigens, 
like viruses, can drive a similar ABC-like program. 
3.1.6 ABCs are associated with humoral autoimmune and autoinflammatory 
diseases 
Beyond their initial identification in aged mice, ABCs prematurely 
accumulate in a variety of autoimmune prone mouse strains.  A considerable 
ABC population accumulates as early as 6 months of age in mice lacking the 
tyrosine kinase, Mer, as well as in NZB/WF1 animals (258).  In accord with these 
findings, ABCs constitute a higher proportion of total B cells in female RA 
patients (258).  Moreover, before their detailed characterization in mice, ABC-like 
cells were also observed in common variable immunodeficient (212) and 
Sjögren's syndrome patients (187).  It is unclear if the CD21-/lo cells in these 
individuals constitute a bona fide ABC population, since they were not 
characterized for CD11c, T-BET, or other subsequently appreciated ABC 
makers. In contrast, a more recent investigation of an early-onset Evan’s 
syndrome patient exhibited premature senescence and an increased number of 
CD11c+TBET+ B cells that correlated with antinuclear antibodies (211). 
Interestingly, duplicating the tripeptidyl peptidase II (TPP2) frame shift mutation in 
mice recapitulated both the disease and ABC phenotype. Thus, ABCs are 
implicated in both human autoimmune syndromes and in murine models of 
humoral autoimmunity. These finding prompt the question of how the 
dichotomous roles of ABCs – providing beneficial and appropriate effector 
functions during intracellular infection but also being associated with humoral 
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autoimmunity – can be mechanistically reconciled. 
3.1.7 Summary of findings 
 In light of IL-21’s novel TBET-inducing capacity described in the previous 
chapter, we sought to investigate whether the proposed model of cytokine 
interplay on TBET+ B cell fates also holds true for ABC phenotype, formation, 
and presumed function.  Thus, we hypothesized that ABCs would adopt a cell 
surface phenotype most compatible with BMEM cells and accumulate into this 
antigen-experienced pool.  Further, adoptive transfer studies suggest that ABC 
formation depends on MHCII antigen presentation and CD40 costimulation.  
Consistent with these results, we find that ABCs are somatically mutated.  
Although causal relationships between ABC formation and autoantibody 
production have not been established, we also observe that aged mice have 
increased serum IgG2c, and anti-dsDNA antibodies are primarily IgG2c.  Finally, 
TFH cells in aged mice produce less IL-4, comparable IL-21, and more IFNγ than 
adult counterparts in response to alum immunization.  The implications of this 
skewed TFH cytokine profile and resulting effects on B cells are discussed. 
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3.2 MATERIALS AND METHODS 
Mice 
I-ab-/- C57BL/6 mice were gift from Dr. Terri Laufer; Cd40-/- spleens were shipped 
overnight from Dr. Mandy Ford’s mouse colony; CD45.1 and CD45.2 C57BL/6, 
and NZBWF1/J mice were obtained from Jackson Laboratory. Aid−/− mice were 
bred at the National Institute on Aging (NIA).  All animal protocols were reviewed 
and approved by the Animal Care and Use Committees at the NIA and the 
University of Pennsylvania. 
Adoptive transfers 
CD23+ splenic B cells were enriched by positive selection using MACS bead 
system (Miltenyi Biotec), subsequently labeled with CFSE (eBioscience) 
according to manufacturer’s instructions, and 8 million were adoptively 
transferred into congenic hosts. 
Flow cytometry 
The same FACS reagents listed in chapter 2 were used with the following 
additions: CD45.1 (A20, BL), CD45.2 (104, BL), Fas/CD95 (clone Jo2). 
Mutational Analyses 
The following gating strategies were used for sorting: FO B cells, CD93 (AA4.1)- 
CD43- B220+ CD21/35+ CD23+; MZ B cells as CD93 (AA4.1)- CD43- B220+ 
CD21/35+ CD23Lo; and ABCs as CD93 (AA4.1)- CD43- B220+ CD21/35- CD23-.  
Cells were lysed in Trizol and RNA was prepared.  cDNA was synthesized using 
SuperScript III reverse transcriptase (Invitrogen).  Immunoglobulin heavy (IgH) 
chain variable, diverse, and joining (VDJ) genes, and kappa light (Igκ) chain VJ 
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genes were amplified using Taq polymerase (TaKaRa, Clontech) with 5’ 
degenerate primers specific to the framework 1 region of V genes and 3’ primers 
located in the IgM or Igκ constant regions as previously described. PCR products 
were then cloned into the Strataclone TA cloning vector (Agilent Technologies) 
and sequenced. Only sequences with unique VDJ or VJ joins were counted. The 
sequences were blasted against the mouse Ig loci using IgBLAST from NCBI to 
identify V, D, and J gene segment usage and mutations.  Lisa M. Russell Knode 
in the Gearhart lab at NIA performed these experiments. 
Serum antibody titers and NP-specific ELISA 
Same procedure as explained in chapter 2 except that ELISA plates were coated 
with 10 µg/ml NP4-BSA, NP33-BSA (Biosearch Technologies). 
Quantitative PCR analysis 
Same procedure as explained in chapter 2. 
Statistics 
Student’s t-test was used to generate all P-values, * P <0.05, ** P <0.01, *** P 
<0.001, **** P <0.0001.  All error bars are S.E.M. based on biological replicates. 
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3.3 RESULTS 
3.3.1 ABCs are phenotypically heterogeneous and accumulate into BMEM 
cell pools 
 Others and we previously established that ABCs are phenotypically 
distinct from other mature subsets and hypothesized that ABCs are a pool of 
antigen-experience, BMEM cells (194, 259, 261).  However, ABCs were reported 
to express CD95, which suggests a GC B cell phenotype.  To interrogate this 
point, we performed a phenotypic analysis on ABCs using a variety of B cell 
activation surface markers.  We find that ABCs bifurcate for CD95 (Fas) 
expression, stain highly for CD38, but are negative for PNA (similar results 
obtained with GL7) (Figure 15A).  As a control, we used mature naïve B cells 
(FO and MZ) and GC B cells (background GCs from a young mouse).  Thus, we 
confirmed prior reports of elevated CD95 expression, but the lack of PNA and 
GL7 suggests that ABCs are not bona fide GC B cells.  Further, CD38 
expression is consistent with a BMEM cell phenotype since mature B and BMEM 
cells express CD38 while GC B cells and PCs do not (266, 267).  Overall, these 
data not only reinforce the idea that ABCs are phenotypically heterogenous, but 
also that they likely inhabit BMEM cell pools. 
In defining ABCs, other groups employed different gating strategies that 
included T-BET and CD11c.  To assess how this phenotypic strategy differs from 
our own, we added these criteria to our FACS parameters.  We find that our 
gating strategy encompasses T-BET+CD11c+ ABCs as described by Rubtsov et 
al (258).  Furthermore, T-BET and CD11c expression defines 3 distinct groups of 
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ABCs: T-BET-CD11c-, T-BET+CD11-, and T-BET+CD11c+ (Figure 15B, left).  
Thus, we asked whether T-BET and CD11c expression correlates with CD95, 
CD38, or IgM.  The data show that all T-BET+ ABC subsets express high levels 
of CD95 and CD38 regardless of CD11c levels, whereas the T-BET- subset is 
low to negative for both of these markers.  Importantly, CD11c+ ABCs had the 
lowest surface IgM expression, which is indicative of class switching (Figure 
15B, far right).  Overall, these data confirm that ABCs are phenotypically diverse 
with respect to isotype and canonical B cell activation markers.  Further, the 
broad expression of surface IgM on ABCs previously reported can be attributed 
to distinct BMEM cell subsets. 
 A hallmark of immunoscenece is the progressive accumulation of memory 
T cells with age (268); however whether BMEM cells increase with age has not 
been interrogated.  If ABCs are BMEM cells that slowly accumulate over the 
lifetime of the host, we reasoned that the switched T-BET+CD11c+ ABCs would 
be a significant part of the BMEM cell pool in aged mice.  Using the phenotypic 
criteria described above, we observed an increased frequency of T-BET+CD11c+ 
into the switched, splenic BMEM cell compartment using the gating strategy in 
Figure 4A (Figure 15C).  Importantly, while the total number of BMEM cells 
increases by 5-fold, we observed a 13- and 22-fold increase of T-BET+ and -
BET+CD11c+, respectively (Figure 15 C & D).  Thus, these switched, T-
BET+CD11c+ ABCs phenotypically resemble the IL-21 driven BMEM cells 
described in the previous chapter. 
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Figure 15. ABCs phenotypically resemble and accumulate into BMEM cell 
pools.  (A)  Representative FACS plots for CD95, PNA, and CD38 stains on GC B, 
FO B, MZ B, and ABCs from 24 month old mice. GC B cells defined as 
GL7+IgM-CD19+B220+CD138-IgD-DUMP-; FO B cells defined as 
CD23+CD21/35loCD93-CD43-B220+CD19+; MZ B cells defined as 
CD23loCD21/35+CD93-CD43-B220+CD19+; ABCs (in red) defined as 
CD23loCD21/35loCD93-CD43-B220+CD19+. (B) FO B cells and ABCs from (A) were 
further probed for T-BET and CD11c. n = 3 independent experiments with >3 mice 
per group. (C) Representative T-BET and CD11c staining on BMEM cells from adult 
and aged mice gated as in Figure 4C. (D) Enumeration of populations in (C) across 
3 independent experiments with 12, 10, and 11 mice aged <6, 12-21, and 22-30 
months, respecively.
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3.3.2 ABC formation requires MHCII and CD40 expression 
We previously showed that ABC-like cells can arise from FO B cells 
following extensive in vivo expansion in adoptive hosts 30 days after transfer 
(194).  In these experiments, the extensively divided cells downregulated CD23 
and CD21/35 and thus resembled ABCs (Figure 15A).  Reasoning that this is a 
proxy for ABC formation, we next tested whether surrogates of cognate help are 
critical for ABC formation.  Thus, we transferred MHC class II (I-ab-/-), Cd40-/-, or 
WT B cells into WT congenic recipients.  A month later, we observe a population 
of donor-derived (CD45.2) B cells (Figure 16A).  Consistent with prior results, 
CFSEhi cells represent the vast majority of transferred cells, whereas some B 
cells had extensively divided (CFSElo) and are low for CD23 (Figure 16B, WT).  
Moreover, these CFSElo B cells adopt an ABC phenotype, including expression 
of T-BET and CD11c (Figure 16C, left panel).  In contrast, both MHCII and 
CD40 deficient B cells yielded fewer extensively divided cells (Figure 16B), and 
among these there was negligible TBET expression (Figure 16C).  These results 
are consistent with the view that ABCs arise from B cells involved in TD immune 
responses because both antigen-presenting capacity and CD40 costimulation 
are required. 
3.3.3 ABCs have undergone SHM and correlate with increased IgG2c 
autoantibodies 
The phenotypic similarity to IL-21 driven cell fates, accumulation into BMEM 
cell pools, and requirement of cognate interactions to form suggests that ABCs 
originate from GC reactions.  If so, then the V genes of ABCs should contain 
Figure 16. Interactions with I-ab and Cd40 drive the accumulation of ABCs.  
(A) CD23+ FO B cells from  C57BL/6 mice (CD45.2) were labeled using CFSE and 
adoptively transferred into young congenic CD45.1 hosts. Recipient mice were ana-
lyzed one month later. Shown is a representative plot of the gating strategy of live, 
singlets of the recipients (CD45.1) and donors (CD45.2), and (B) representative dot 
plots showing the dilution of CFSE in wild type (n=19), I-ab-/- (n=11), Cd40-/- (n=17) 
mice across 3 independent experiments. CFSElo defined as more than 4 divisions. 
(C) Histograms show staining for T-BET in indicated populations. 
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increased frequencies of mutations compared to other subsets.  In collaboration 
with the Gearhart lab, we counted the number of mutations in VDJ and VJκ exons 
amplified from sorted FO, MZ, and ABC B cell subsets, and compared the V, D, 
and J sequences to their germline counterparts to identify mutations.  Sequences 
from ABCs had a significant, four-fold increase in mutations compared to FO 
cells and a significant two-fold increase compared to MZ cells (Figure 17A).  As 
a control, V exons were sequenced from FO and MZ cells from young Aid-/- mice, 
which do not undergo hypermutation.  The mutation frequency was 
approximately 2x10-3 mutations per bp for Aid-/- cells, which represents the 
background frequency of errors produced during cDNA synthesis and PCR 
amplification.  Thus, ABCs have undergone AID-mediated somatic mutation. 
In addition to SHM, AID also mediates CSR.  Since B cell intrinsic T-BET 
expression fosters switching to IgG2c, we reasoned that the accumulation of T-
BET+ BMEM cells would correlate with increased serum IgG2c in aged mice.  
Indeed, analysis of serum IgG subtypes reveals that serum IgG1 concentrations 
remain unchanged between young and aged mice; however, IgG2c is nearly 10-
fold higher in aged mice (Figure 17B).  Finally, the emergence of increased 
serum anti-DNA autoantibodies titers is another well-documented hallmark of 
immunosenescence (234).  Thus, we reasoned these autoantibodies in aged 
mice would also be of the IgG2c isotype.  Using the autoimmune prone mouse, 
NZ(BxW)F1 as a positive control, we observe that most of the dsDNA reactive 
antibodies are of the IgG2c rather than IgG1 isotype in aged mice, whereas young 
mice served as negative controls for both isotypes (Figure 17C).  Overall, these  
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Figure 17. ABCs undergo SHM and correlate with  IgG2c autoantibody. (A) 
Only unique sequences were analyzed for mutations in the V, D, and J gene seg-
ments. Mean mutation frequencies (mutations/nucleotides) in the VDJ and VJκ 
exons of each B cell subset were calculated. The dotted line indicates the back-
ground mutation frequency in Aid-/- FO and MZ B cells from young mice. * = P < 
0.0001, Chi-squared test. (B) Total serum IgG1 and IgG2c in 4 (n=11) and 24 (n=15) 
month old mice. (C) dsDNA reactive IgG1 and IgG2c antibody titers in aged (n=6), 
adult (n=5), and NZ(BxW)F1 (n=1) mice.
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observations are consistent with the idea that ABCs are likely a population of 
somatically mutated, class-switched, BMEM cells arising from interactions with IL-
21 and IFNγ producing TFH cells.  However, there is no clear causal connection 
between the increase of both T-BET+ ABCs and IgG2c autoantibodies. 
3.3.4 TFH cells produce less IL4 and more IFNγ in aged mice 
 As discussed previously, TFH cells instruct antibody isotype determination 
via cytokine production.  Therefore, given the skewing towards IgG2c observed in 
aged mice, we asked whether these TFH cells are skewed in their cytokine 
production profile.  We reasoned that TFH cells in aged mice would produce less 
IL4 or more IL21 and/or IFNγ.  Therefore, we immunized mice with NP-OVA 
precipitated in aluminum salts, which drive a robust IgG1 antibody response 
(although other isotypes are also produced) against the immunizing agent via the 
production of IL-4 from TFH cells.  Using the gating strategy shown in Figure 8A 
& 11A, we sorted TFH cells from immunized mice.  Consistent with prior aging 
reports, we observed a substantial decrease of naïve, CD62L+ CD4 T cells in 
aged mice compared to adults (Figure 18A).  Next, we probed for IL-21, IL-4, 
and IFNγ mRNA from sorted TFH cells.  The data show that while IL-21 mRNA 
levels remained similar between aged and adult mice, TFH cells in aged mice 
produced far fewer IL-4 and substantially more IFNγ transcripts (Figure 18B).  
These data suggest that the resulting antibody response would be skewed 
towards IgG2c rather than IgG1 in aged mice; however, this prediction does not 
hold true.  Instead, consistent with many prior reports, the humoral immune 
response in aged mice is severely blunted.  Using high (NP25, Figure 18C) and 
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low (NP4, Figure 18D) substitution ratios of hapten-carrier conjugates, we can 
detect low and high affinity antibodies, respectively.  Thus, while adult mice 
produced affinity matured NP-reactive antibodies of both isotypes, aged mice 
produced far fewer antibodies of all affinities and isotypes.  Thus, even though 
TFH cells produce equivalent amounts of IL-21 between young and aged mice, 
reduced IL-4 production is not sufficient to drive IgG2c in aged mice as observed 
in Il4-/- mice and HP infection (Figure 12C). 
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Figure 18. Aged TFH cells produce less IL-4 and more IFNγ.  (A) FACS stained 
splenocytes from day 14 post NP-OVA immunized adult and aged mice. (B) Gene 
expression analysis (ΔΔCt) for Il21, Il4, and Ifng from sorted TFH cells from (A).   
Serum titers for (C) NP25 (low affinity) and (D) NP4 (high affinity) reactive IgG1 or 
IgG2c antibodies from (A).. Figures are represenatative across 3 experiments with ≥
3 mice per group.
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3.4 DISCUSSION 
 Together these data suggest that ABCs constitute a pool of antigen-
experienced, BMEM cells that tend to express TBET.  Phenotypic analysis reveals 
that ABCs are heterogeneous and accumulate into BMEM cell compartments.  
Consistent with this idea, we used a proxy of ABC generation and determined 
that their formation is dependent on both antigen presentation via MHCII and 
costimulation through CD40.  Moreover, the marked increase of somatic 
mutations in VDJ and VJκ exons further confirms that ABCs require T cell help for 
their formation and may originate from GC reactions.  Furthermore, consistent 
with its role in class switching, T-BET expression in ABCs correlates with 
increased total and anti-dsDNA IgG2c.  Finally, cytokine profiling of TFH cells in 
aged mice reveals that they lose the capacity to produce robust IL-4 but make 
substantial IFNγ.  However, the antigen-specific humoral response is significantly 
reduced and not skewed towards the IgG2c isotype as the TFH cytokine profile 
would suggest.  Overall, these data suggest that ABCs constitute a pool of BMEM 
cells and require IL-4-limited T cell help to form. 
Phenotypic analysis of ABCs provides important clues about their 
presumed function and origin.  Using well-defined markers associated with GC B 
and BMEM cell fates (Table I), we find that ABCs express CD95, but not PNA or 
GL7 suggesting they are not GC B cells (Figure 15A).  Moreover, high 
expression of CD38 is consistent with a BMEM cell phenotype, and CD95 
expression has been previously reported on BMEM cells (269).  Importantly, 
TBET+ ABCs uniformly express CD95.  While we speculate that CD95 
 
 
 
 
75 
expression may functionally sensitize ABCs to FasL-mediated cell death, many 
other survival factors may overcome this extrinsic apoptosis pathway (270). 
Furthermore, initial ABC phenotypic analysis revealed that they bear broad 
surface IgM expression (194).  Dividing them further by T-BET and CD11c 
reveals that the TBET+CD11c+ subset is mostly negative for IgM (Figure 15B).  
Although it is unclear whether this is due to a TD or TI response, the data 
indicate these ABCs have undergone CSR.  Consistent with this, T-BET+CD11c+ 
ABCs accumulate into the switched BMEM compartment (Figure 15C & 15D).  
Overall, these phenotypic data support the notion that ABCs are a 
heterogeneous population of BMEM cells.  However, the origins and necessary 
cellular interactions for ABC formation remain unclear. 
 When first described, ABCs were found to be sensitive to sub-lethal 
ionizing radiation and did not rebound from aged progenitor B cells in the BM 
(194).  Moreover, ABC accumulation was proportional to a decrease in mature 
FO B cells.  Thus, ABCs were thought to originate from mature B cell pools.  
Adoptive transfers of FO B cells into congenic hosts revealed that extensive 
division was sufficient to generate an ABC phenotype (i.e. CD23-CD21/35-).  
Positive staining for T-BET and CD11c further confirmed that these extensively 
divided B cells phenotypically resemble ABCs (Figure 16C).  Importantly, 
extensive division and T-BET staining were largely abrogated when B cells could 
not present antigen or receive costimulation.  In these cases, some cells did 
divide likely reflecting homeostatic expansion.  Assuming that this assay is a 
proxy of ABC generation, these data indicate that cognate interactions between T 
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and B cells are required for ABC formation.  In addition to the mutational analysis 
(Figure 17A), we further conclude that ABCs may originate from GC reactions.  
However, recent reports highlight an important role for the extrafollicular 
response in autoimmune etiology (271, 272).  These responses also require IL-
21 and MHCII expression on B cells for SHM and disease progression (273, 
274).  Therefore, since ABCs tend to accumulate more quickly in these 
autoimmune mice, both the extrafollicular and GC responses must be considered 
as sources of ABC generation.  While the data presented here cannot distinguish 
between the two possibilities, we suggest that ABCs are a product of cognate T 
cell interactions with limited IL-4 and abundant IFNγ and IL-21. 
A long-standing observation of age-related immune dysfunction is the 
emergence of autoantibodies (234).  Although murine autoantibodies were 
reported to be IgG (237), subtype analysis was never performed.  Thus, it is 
tempting to speculate that the increase in total and anti-dsDNA IgG2c antibodies 
is due to T-BET+ ABC accumulation (Figure 17B & 17C); however, currently 
these associations are purely correlative.  While the tempo of ABC accumulation 
dramatically increases in autoimmune prone mice, bone fide ABCs in otherwise 
healthy aged mice are yet to be rigorously tested for overt self-reactivity.  
Nonetheless, if ABCs constitute a BMEM cell pool of autoreactive specificities, 
then it would also be worthwhile to investigate whether they maintain 
autoantibody titers by feeding into the PC compartment.  Moreover, the 
preferential accumulation of IgG2c autoantibodies is important because the type 
of IgG generated has profound effects on subsequent antibody effector function.  
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Indeed, while antigen-binding capacity is crucial, the heavy chain isotype 
determines functionality via binding to FcγRs, which are expressed on a variety 
of myeloid cells and enhance effector functions such as ADCC, phagocytosis, 
and opsonization (14).  Moreover, FcγRs can be inhibitory or activating 
depending on whether the cytoplasmic tail bears an ITIM or ITAM, respectively 
(275).  Importantly, IgG2c binds to all 3 activating and 1 inhibitory FcγRs whereas 
IgG1 only binds to one of each (276).  Therefore, the result that most anti-dsDNA 
antibodies in aged mice are IgG2c (Figure 17C) suggests that myeloid cells 
receive increasingly proinflammatory signals when DNA-IgG2c complexes 
engage ITAM-bearing FcγRs receptors.  Although the lack of standards makes 
absolute quantification impossible, whether the nearly 10-fold increase of total 
serum IgG2c in aged mice is significantly composed of autoreactive specificities is 
an important future consideration (Figure 17B). 
Overall, these data indicate that ABCs likely represent a pool of BMEM cells 
resulting from cognate interactions with IFNγ or IL-21 producing T cells.  
Because these cytokines may originate from TFH cells, we wanted to know 
whether TFH cells in aged mice have a cytokine production profile that is 
permissive to the ABC phenotype.  Indeed, TFH cells from aged mice made less 
IL-4 and equivalent IL-21 to adults (Figure 18B), and thus we reasoned that the 
resulting NP-reactive antibodies would be IgG2c instead of IgG1 as we had 
observed with HP infection in Il4-/- mice (Figure 12C).  Unsurprisingly, the most 
consistent result was a diminished antibody response both in terms of quantity 
and affinity regardless of isotype (Figures 18C & 18D).  While it is difficult to 
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dissect cause and effect, there exist a number of possibilities.  We cannot 
conclude that aged TFH cells are intrinsically incapable of producing IL-4, since 
improper priming in the aged microenvironment could also explain these data. 
Importantly, TFH cells require two independent antigen presentation events from 
both a DC and B cell to adopt full effector status (87).  Thus, currently it is 
impossible to know whether the aged T cell itself, DC, or B cell explain the 
decrease in IL-4 and robust IFNγ production.  However, when used as APCs in 
vitro, ABCs have been shown to aberrantly skew T cells (194); therefore, it is 
tempting to speculate that ABCs may contribute to this shift in cytokine 
production in vivo.  Lastly, aged TFH cells made substantially more IFNγ than 
adults.  It is documented that anti-IFNγ treatment reinvigorates the aged humoral 
response back to adult levels (277), thus we consider that excess IFNγ in aged 
mice may hinder the GC response.  Overall these data indicate that TFH cells in 
aged mice have a skewed cytokine profile, but that does not correlate with 
expected antibody isotype outcomes. 
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4. PERSPECTIVE 
ABCs impact a broad spectrum of immunological phenomena, including 
protective immunity to some pathogen classes, immunosenescence, and 
autoimmunity. In mice, ABCs constitute an accumulating population of B cells 
with unique surface phenotype, signaling properties, and effector status. While 
initially described in aged mice, phenotypically and transcriptionally identical cells 
are observed in humoral autoimmunity and immune responses against 
intracellular pathogens in both mice and humans. These observations lead us to 
propose that ABCs are a memory B cell population, and that the signals and 
interactions that yield ABCs in both normal and autoreactive humoral responses 
are comparable; these consist of concomitant signals from the BCR, nucleic acid 
sensing TLRs, and inflammatory cytokines. Thus, understanding how responses 
to endogenous versus exogenous nucleic acid-bearing ligands are regulated in 
order to maintain tolerance yet allow appropriate responses to pathogens should 
yield insights relevant to both protective and autospecific humoral immunity. 
Inasmuch as ABCs were first detected by virtue of their progressively 
increasing representation with age, the question arises as to whether they 
contribute to age-associated alterations in immune activity and immune 
responsiveness.  This seems likely based on their unique spectrum of activation 
requirements, antigen presenting capacity, and effector cytokine profile, and 
several recent findings support this notion. 
First, recent studies suggest that ABCs may be instrumental in the 
decreased B lymphopoiesis associated with age.  Ratliffe et al assessed the 
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proportion of ABCs in mice at different ages, and found that the degree of B 
lymphopoiesis depression was proportional to ABC representation with age 
(260). Moreover, they showed that ABCs are a potent source of TNFα, and that 
this cytokine was in part responsible for inhibiting the survival of B lineage 
precursors in vitro and in vivo. These observations, coupled with the ability of 
ABCs to occupy homeostatic space to the detriment of preimmune FO B cells, 
are particularly intriguing in light of reports that B lymphopoiesis and robust 
humoral responses can be rejuvenated in aged individuals by B ablative regimes 
(278-282). 
Second, recent studies have revealed aspects of TFH generation that rely 
on cognate B cell interactions differ in young and aged mice. For example, 
several laboratories have shown that optimal IL-21 and IL-4 production among 
dendritic cell-primed TFH cells only occurs following antigen presentation by B 
cells (87, 283, 284). However, under in vivo immunization conditions that 
normally foster this TFH profile, aged individuals fail to generate TFH cells with the 
characteristic upregulation of IL-4 (210). While causal links have not yet been 
forged, it is tempting to speculate that ABC antigen presentation may foster at 
TFH cytokine profile that lacks IL-4. Alternatively, TFH cells generated in aged 
individuals may intrinsically skew towards a cytokine profile lacking IL-4, which 
might be instrumental in driving ABC generation. 
Third, in addition to the decline of B lymphopoiesis and functional T cell 
alternations, an increase in anti-dsDNA, anti-nuclear, and other autoantibodies 
occurs in both mice and humans (234, 237, 285, 286). Indeed, ABC 
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accumulation correlates with serum autoantibody levels, and ABCs isolated from 
aged mice and stimulated with a TLR7 agonist produced anti-chromatin (258). 
While not PCs, ABCs could constitute a pool of BMEM cells that feed a population 
of autoantibody secreting PCs. Thus, while ABCs accumulation has a number of 
correlative associations with B cell development, altered T cell functionality, and 
autoantibody production, causality is yet to be established. 
ABCs in aged, virally infected, and autoimmune-prone mice and humans 
share a common triumvirate of stimuli for their origin: BCR signals, nucleic acid 
sensor ligation, and a type-I inflammatory cytokine milieu.  This commonality is 
likely the link that connects beneficial and pathogenic ABC formation. In 
particular, the role of endosomal nucleic acid sensors driven by BCR-acquired 
antigens may prove the most important feature. Over the past decade the 
contribution of nucleic acid sensing PRRs, particularly TLR7 and TLR9, to the 
etiology of autoimmune disease have come to forefront.  Beginning with the 
seminal observation that BCR delivered nucleic acid ligands have distinct 
survival and proliferative potentials for B cells (287), it has become increasingly 
apparent that TLR7 and TLR9 both promote and regulate the progression of 
humoral autoimmunity.  To test this idea, Shlomchik’s group bred SLE-prone 
mice to either TLR7 or TLR9-deficient mice (208, 288). Because extra Tlr7 gene 
copies results in an SLE-like disease (289), it was expected that TLR7 deficiency 
would ameliorate disease in autoimmune-prone mice. While this hypothesis was 
indeed validated, TLR9 deficiency unexpectedly exacerbated disease (206, 208). 
This suggests not only a regulatory role for TLR9 but also differential disease 
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outcomes based on whether autoreactive B cells can sense RNA or DNA 
moieties. These ideas are further confounded by the fact that TLR9 deficiency in 
other models of autoimmunity ameliorates disease (290). Though the mechanism 
by which TLR9 limits while TLR7 promotes disease remains unclear, recent 
findings suggest a role for type-I interferon signaling for disease etiology (291). 
Whether ABC formation occurs in these models of autoimmunity and whether 
TLR7 and TLR9 modulate ABC accumulation is yet to be established. Thus, the 
signals from the BCR, nucleic acid sensing TLRs, and inflammatory cytokines – 
while exactly those involved in appropriate ABC-mediated immunity – are exactly 
those that, when dysregulated, foster humoral autoimmunity. 
While the interplay of IL-4, IL-21, and IFNγ dictate the assumption of T-
BET+CD11c+ B cells in the context of TLR engagement, the functional 
consequences of making such cells remains elusive.  Our infection and aging 
studies reveal that ABCs phenotypically resemble BMEM cells; however, bona fide 
BMEM cell function is not shown.  Adoptive transfers of T-BET+CD11c+ BMEM cells 
from PR8 primed Il4-/-ifng-/- mice (Figure 9A) into naïve recipients followed by 
lethal PR8 challenge would begin to address whether these cells are sufficient to 
mediate protection.  If the recipients survive, then ABC-like cells observed in viral 
infection do indeed constitute a functional pool of BMEM cells.  Moreover, 
challenge with a heterologous virus may also elucidate a non-redundant role for 
these cells independent of high affinity antibody.  Indeed, it is suggested that 
BMEM cells are less somatically mutated than their PC counterparts and are thus 
more promiscuous in their specificity.  In this regard, the established PCs and 
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antibodies are blind to escape variants.  Thus, BMEM cells may be better suited to 
protect the host against variants of the original infectious agent. 
T-BET expression may also provide further clues about ABC function.  
While T-BET’s role in fostering CSR to IgG2a/c is well-established in B cells, other 
studies (133) and our data show that a substantial amount of PR8-specific IgG2c 
is independent of T-BET (Figure 9C).  Thus, while B cell intrinsic T-BET 
expression is necessary to control viremia (137), T-BET may be orchestrating 
other key cellular programs independent of CSR to IgG2a/c.  Indeed, T-BET has 
been shown to drive many cellular processes including proper chemotaxis, 
metabolism, maintenance, and homeostasis (111, 129, 131, 132, 292).  Our 
transcriptionally analysis (Figure 3B) confirm T-BET’s pleiotropic effects since 
many genes involved in trafficking and metabolism are affected by T-BET 
deficiency in addition to those necessary for SHM and CSR.  Thus, does T-BET 
deficiency alter BMEM cell trafficking patterns or homeostatic maintenance?  To 
answer this question, Cd19Cre/+Tbx21f/f mice infected with PR8 would reveal 
whether protective BMEM cells traffic properly to sites of infection without T-BET, 
i.e. the lung.  Moreover, establishing a pool of T-BET+ BMEM cell pool via PR8 
infection in hCD20-TamCre x Tbx21f/f mice followed by tamoxifen-mediated 
deletion of T-BET would address their maintenance requirements.  Furthermore, 
long-term studies could also assess whether T-BET+ BMEM cells are necessary 
for the maintenance of PR8 specific PC numbers and antibody titers.  In each 
experiment, adoptive transfers BMEM cells from PR8 immune mice where T-BET 
has been deleted into naïve recipients would be necessary to prove whether they 
 
 
 
 
84 
are protective independent of pre-established antibody titers.  Thus, while our 
data establish a role for IL-21 in mediating this cell fate, more studies are 
necessary to determine functionality. 
These observations and future directions lead us to propose the model 
depicted in Figure 19. In general, any nucleic acid containing antigen harbors the 
capacity to drive an ABC phenotype. However, growing evidence suggests that T 
cell derived proinflammatory cytokine signals, as well as cognate help, may be 
required to engender a long-lived ABC fate. In this regard, an activated B cell 
presenting viral peptides can efficiently receive all three signals required for 
recruitment into long-lived effector subsets. In contrast, autoreactive B cells 
binding nucleic acid containing self molecules, such as apoptotic debris or other 
sources, while receiving BCR and TLR signals will fail to receive further cues for 
survival, resulting in short-lived responses or death. However, inadvertent or 
aberrant recruitment of such short-lived autoreactive cells into long-lived effectors 
would thwart this peripheral tolerance system, and yield sustained autoantibody 
and auto inflammation driven by IgG2a/c production. Multiple routes to such 
dysregulation could be envisioned, including overabundance of autoantigen or 
deficiencies in the molecules that mediate these regulatory circuits. 
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Figure 19. Both beneficial and pathogenic ABCs arise via a common triad of 
signals.   Preimmune FO, MZ, and/or TR B cells bind, internalize and traffic anti-
gens to endocytic compartments via the BCR. Pathogen degradation leads to viral 
nucleic acids engaging TLR7 or TLR9.  Processing and loading of viral peptides 
onto MHCII molecules results in cognate CD4 T cell interactions and T cell derived 
inflammatory cytokine secretion. The combination of these signals leads to T-BET+ 
memory and effectors, and to IgG2a/c isotype switching. Normally, B cells that inter-
nalize nucleic acid containing self-antigens fail to survive because they lack the 
cognate T cell interactions and appropriate cytokine signals to further differentiate 
and survive.  However, inadvertent or aberrant receipt of these signals can afford 
survival of these self-reactive cells and enable their recruitment into a long-lived 
memory and effector ABC pool.
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